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ABSTRACT OF DISSERTATION

COMPUTATIONAL DESIGN OF 3-PHOSPHOINOSITIDE DEPENDENT KINASE-1
INHIBITORS AS POTENTIAL ANTI-CANCER AGENTS
Computational drug design methods have great potential in drug discovery
particularly in lead identification and lead optimization. 3-Phosphoinositide dependent
kinase-1 (PDK1) is a protein kinase and a well validated anti-cancer target. Inhibitors of
PDK1 have the potential to be developed as anti-cancer drugs. In this work, we have
applied various novel computational drug design strategies to design and identify new
PDK1 inhibitors with potential anti-cancer activity. We have pursued novel
structure-based drug design strategies and identified a new binding mode for celecoxib
and its derivatives binding with PDK1. This new binding mode provides a valuable
basis for rational design of potent PDK1 inhibitors. In order to understand the
structure-activity relationship of indolinone-based PDK1 inhibitors, we have carried out
a combined molecular docking and three-dimensional quantitative structure-activity
relationship (3D-QSAR) modeling study. The predictive ability of the developed
3D-QSAR models were validated using an external test set of compounds. An efficient
strategy of the hierarchical virtual screening with increasing complexity was pursued to
identify new hits against PDK1. Our approach uses a combination of ligand-based and
structure-based virtual screening including shape-based filtering, rigid docking, and
flexible docking. In addition, a more sophisticated molecular dynamics/molecular
mechanics- Poisson-Boltzmann surface area (MD/MM-PBSA) analysis was used as the
final filter in the virtual screening. Our screening strategy has led to the identification of
a new PDK1 inhibitor. The anticancer activities of this compound have been confirmed
by the anticancer activity assays of national cancer institute-developmental therapeutics
program (NCI-DTP) using 60 cancer cell lines. The PDK1-inhibitor binding mode
determined in this study may be valuable in future de novo drug design. The virtual
screening approach tested and used in this study could also be applied to lead
identification in other drug discovery efforts.
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CHAPTER 1

1. INTRODUCTION
Computational drug design is a fast growing field and it has emerged as a major
player to design new drugs in a rational manner. In this work, the application of
computational drug design techniques including structure-based drug design,
ligand-based

three-dimensional

quantitative

structure-activity

relationship

(3D-QSAR) methods and combined virtual screening approaches were studied using
a well known anti-cancer target 3-phosphoinositide dependent kinase-1 (PDK1).
These computational drug design approaches have been successfully applied to both
lead optimization and hit identification against PDK1. In this chapter the
background information about computational drug design and PDK1 are presented.

1.1 Computer-aided drug design
Drug discovery is broadly defined by Burger as the process that includes
identification and validation of a therapeutic target, development and validation of
suitable assays, lead identification and characterization in vitro, lead optimization,
formulation, pharmacological studies, pharmacokinetic and toxicity studies in
animals, followed by three phases of clinical trials in humans. 1 This description of
drug discovery itself underlines the fact that it is a very long and expensive process.
Discovery and development of a single drug is estimated to take 12 to 24 years.2 It
is reported that the average cost to develop a new drug into market is more than
US$800 million before 2004.3 Historically, Paul Ehrlich postulated on the existence
of chemoreceptors that can be exploited therapeutically and it marked the beginning
of the modern drug therapy.4 Initial focus was reported to be on the isolation and
purification of active ingredients from natural products.4 This evolved into the trial
and error process of synthesis and in vivo screening of compounds leading to
serendipitous discovery.2 This was followed by rational approaches which were
based on studying the underlying molecular mechanism involved and understanding
the drug-receptor interactions.4 Despite this systematic approach, the number of new
1

chemical entities (NCE) that are approved for market was reported to be declining in
the recent years.5 Only 18 NCEs were reported to be approved in the year 2005 and
2006.6 There was a need for newer technologies to increase the efficiency of drug
discovery process. 7 In this scenario, different experimental and computational
approaches were developed to address the issues in drug discovery process. Some of
the new approaches include combinatorial chemistry, high throughput screening and
computational drug design.8 Among these new technologies, computational drug
discovery has been successful and helps to increase the efficiency of the drug
discovery process.7 Computational drug design is also commonly known as
molecular modeling or computer-aided drug design (CADD). Cohen defines
computational drug design as the approach “which uses a range of computerized
techniques based on theoretical chemistry methods and experimental data that can
be used to analyze molecules and molecular systems and to predict molecular and
biological properties”. 9

Simply this approach is the use of computers and

computational methods to design and discover new drug molecules.10 The increase
in computing power, the availability of cheaper computers and development of new
modeling software has increased the usefulness of this approach.11

Rather than

being a separate process, computational modeling is more useful when integrated
with experimental studies.7 CADD approaches are being implemented in all stages
of drug discovery cycle namely target identification, lead identification, lead
optimization, prediction of absorption, distribution, metabolism, elimination, and
toxicity (ADMET) properties and design of compound libraries. 12 The main
advantage of computational drug design is that it is faster and cheaper than other
experimental approaches.12 This approach is reported to play an active role in both
lead identification and optimization. Computational drug design is reported to have
played a major role in the successful development of marketed drugs like HIV
protease inhibitor Viracept and the anti-influenza drug Relenza.13 In these cases,
computational approaches were used to predict the activity of the designed inhibitor
prior to synthesis and testing.14 Thus it helps to guide the experimental work and
prioritize synthesis of the next compounds. Recently reported studies suggest that
2

computational drug design is also an important component for open-source drug
discovery projects. 15 , 16 Different sources are being explored to carry out
computational drug design in a cheaper way. A project called the ‘screen saver
project’ made use of the free computer time (screen saver time) of users throughout
the world and successfully carried out computational screening against many
therapeutic targets and identified new hits.17 There are two broad strategies in
computational drug design. They are
1. Ligand-based drug design
2. Structure-based (or Receptor-based) drug design
Ligand based drug design (LBDD) which is also known as indirect drug design
make use of the ligand molecule or a series of ligand molecules as the starting point
and explore their properties to identify better lead molecules.7,8 Based on the study
of known ligands a hypothetical receptor active site can be proposed. 18 The
structure based drug design which is also known as direct drug design make use of
either a solved X-ray crystal/NMR structure or modeled structure of the target
protein or other macromolecule.7,19 This target structure is used as the starting
point.19 The binding mode of ligand is then studied to design new ligands with
increased affinity to the target.19

3

QSAR
Ligand-Based
Pharmacophore

Drug Design

Modeling
Shape-based
Screening

Computational
Drug Design

Docking
Structure-Based
Drug Design
De Novo
Drug Design

Figure 1.1 Flowchart of computational drug design strategies

1.1.1 Ligand-based drug design
The structures of protein or other macromolecules are not available for many of
the potential drug targets. In such cases, ligand-based drug design strategies can be
utilized.7 These strategies are based on the concept that biological activity depends
on the ligand’s structure, molecular constitution and charge distribution.20 When a
series of ligands with their biological activity are available, then attempt can be
made to correlate their structure with their biological activities. 21 Quantitative
structure-activity relationship (QSAR) is the “technique that quantifies the
relationship between structure and biological data”. 22 It involves the study of
descriptors to mathematically correlate the chemical structure with biological
activity.23

The descriptors are parameters which are used to represent the structural

features in numerical values.24 The different types of descriptors commonly used in
QSAR models include lipophilicity parameter like LogP, electronic descriptors like
Hammet’s constants and dipole moments, geometrical descriptors like Taft’s steric
parameter and Verloop’s STERIMOL parameters, and finally topological descriptors
4

like molecular connectivity index.20,25 Three essential prerequisites for developing a
QSAR model are “1) descriptors of the chemical’s structure 2) measures of the
chemical’s activity and 3) statistical techniques to quantify the relationship”.20 The
most attractive feature of the QSAR model is that the activity of new molecules to
be synthesized in a series could be predicted.21 QSAR methods have some common
assumptions. They are 1) the compounds in the series being studied interact with the
same biological target through non-covalent interactions; 2) structurally similar
compounds interact in the same pocket and are similarly oriented in the active site.7
The dynamics of the receptor system are usually neglected in ligand-based studies.7
The first QSAR model was reported by Hansch et al.26,27 It was developed by
relating the biological activity to various physico-chemical parameters using suitable
statistical regression analysis. The type of QSAR approach which uses the
physicochemical properties as molecular descriptors is commonly known as the
Hansch approach or linear free energy relationships (LFER) approach.

28

Free-Wilson approach is another type of QSAR method in which indicator variables
that denote the presence or absence of particular groups were used as descriptors
instead of the physicochemical properties.28 In addition to predicting the activity of
new molecule, the QSAR model can also provide information on the mechanism of
action of the compounds.22 It also helps to understand the different aspects of
chemical-biological interaction.29 Some of the successful application of 2D-QSAR
has been reported in the literature.30,31 Some of the limitations of the 2D-QSAR
methods include 1) the lack of physicochemical parameters for either the whole
molecule or its substituents; 2) the absence of 3D molecular properties which are
expected to better explain the receptor-ligand interactions.32 The 3D-QSAR tried to
address the deficits of 2D-QSAR methods. 3D-QSAR models are “quantitative
models that relate the biological activity of small molecules with their properties
calculated in 3D space”.7 Some of the well known 3D-QSAR methods are
Comparative Molecular Field Analysis (CoMFA), Comparative Molecular Similarity
Indices Analysis (CoMSIA), Molecular Field Analysis (MFA) and Receptor Surface
Analysis (RSA).33,34,35
5

Some of the general steps involved in 3D-QSAR are: identification of bioactive
conformation which is usually used as the template, alignment of compounds to the
template, computation of molecular properties, correlation analysis of these
properties with activity, and visualization of regions around the molecule which are
either favorable or unfavorable for activity.32 Alignment of different compounds
using similar groups or common atoms is one of the crucial steps in many 3D-QSAR
methods.36 The major advantages of 3D-QSAR is the ability to predict the activity
of new molecules which is not used in the development of the model as well as the
presence of contour maps showing favorable and non-favorable areas around the
molecules in 3D-space.37
Pharmacophore modeling and shape based screening are the other ligand-based
drug design methods. Pharmacophore can be defined as the three dimensional
representation of essential chemical features of a compound needed for its biological
activity. 38 A 3D pharmacophore gives “the relationship between the groups or
chemical features, by defining distance ranges between groups, angles between
groups or planes, and exclusion spheres”. 39 Based on the structure-activity
relationship of diverse ligands the common pharmacophore can also be
identified.40,41 Once a pharmacophore is developed, it can be used in 3D database
searching to retrieve novel compounds that would match the pharmacophore,
without having the topological features of known active compounds.42 Thus it helps
to identify new class of molecules. Some of the most commonly used programs for
pharmacophore development are Catalyst, Phase and Ligand scout.38 More recently
the shape of the known ligand was successfully used in virtual screening process to
carry out scaffold hopping or to find new inhibitors from database searching.43

1.1.2 Structure-based drug design
Structure-based drug design (SBDD) methods are used when the detailed
structural information of the macromolecular target is available.39 Docking studies
and de novo drug design are two different methods used in structure-based drug
design.8 SBDD is now considered as an integrated part of drug discovery cycle.44
6

The main theme of SBDD is to find ligands complementary to the receptor active
site. Hence the structure of the macromolecular target is essential.39 If the
experimentally solved structure of the target is not available, computational
modeling methods like homology modeling or ab initio modeling can be used.45,46
The modeled structures can then be used to study the ligand-receptor interactions.
The docking process helps to understand the structure-activity relationship of known
ligands based on their molecular level interactions with the active site residues.47
Visual analysis of docked results allows us make chemical modifications in a
rational manner. The two important aspects of docking algorithm are 1) to find the
correct binding mode and 2) to estimate the binding energy and rank order a given
series of ligands.48 Virtual screening is the process by which whole databases of
molecules were screened against target of interest to identify new hits.13 The
identified compounds can then be either synthesized or purchased from commercial
sources and tested for activity.13 This computational screening strategy helps to
refine millions of virtual compounds in silico and reduces the amount of actual
experimental tests needed.49 Different docking programs currently available include
FlexX, Fred, Dock, AutoDock and Glide.39,50 The docking programs are limited by
their ability to consider protein dynamics, solvation and entropic effect of ligand
binding.51,52 De novo design involves design of totally new inhibitors using only the
active site as the starting point.8 In this case, fragments which are complementary to
the different regions of active sites were identified and then joined using suitable
linker groups.8 The problem with this strategy is that some computationally designed
compounds could not be synthesized.

1.2 3-Phosphoinositide dependent kinase-1 (PDK1) as a test case
1.2.1 Cancer
Cancer is defined as a group of diseases characterized by uncontrolled growth
and spread of abnormal cells.53 It is a life-threatening disease condition worldwide.
A total of 7.6 million people were estimated to have died due to cancer worldwide in
the year 2008 alone.54 Others have estimated that the global cancer burden will
7

increase to 27 million new cases by 2050.55 In USA, cancer is the second most
common cause of death. 56 According to the American cancer society, nearly
1,437,180 new cancer cases are expected to be diagnosed in 2008.53 It is estimated
that cancer death rate will be 1500 people per day in USA alone.53 Cancer can
develop in any individual at any time in their lifetime. But the risk of being
diagnosed with cancer is reported to be increasing with age.57 Nearly 80% of all
cancers are diagnosed in patients age 55 and older.57 About 12% of childhood deaths
in USA are due to cancer.55 The overall cost of medical treatment of cancer in 2007
is reported to be $89 billion in USA alone.53 More than 100 different types of
cancers were reported so far.58 Among the different types of cancers, lung cancer is
reported to be the major type of cancer occurring worldwide.59 In the year 2000
itself 1.1million deaths were reported to be due to lung cancer.59 The Prostate, lung
and colorectal cancers are the three most commonly diagnosed cancers in men living
in developed countries.55 Breast, colorectal and lung cancer are the three most
commonly occurring cancer in women living in developed countries.55 In
developing countries the most commonly diagnosed cancers are lung, stomach and
liver in men, and breast, cervix and stomach in women.55 Leukemia and lymphoma
are reported to be the most commonly occurring cancer in children in most
countries.60 The leading sites producing cancer mortality for males and females in
the year 2007 were given in Figure 1.2 and Figure 1.3
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Figure 1.2 Leading sites producing cancer mortality reported worldwide for males.
Graph created using the data reported in ref. 55.
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Figure 1.3 Leading sites producing cancer mortality reported worldwide for females.
Graph created using the data reported in ref. 55.
The mechanism by which cancer is produced in an organism is reported to be
multifactorial, multistage and complex process. 61,62 The current dominant view
regarding the molecular basis of human cancer is that it is due to the “accumulation
of multiple mutations within genes of a single cell that drives the neoplastic
9

transformation, ultimately leading to tumorigenesis”.63
The molecular mechanisms involved in carcinogenesis and the pattern of spread
of cells from the primary site is reported to differ in different types of cancers.58 In
spite of these differences, cancer cells were reported to exhibit some characteristic
features. Hanahan et al. have defined six hallmarks that are present in most of the
cancers. 64 The six hallmarks of cancer are: “1. Acquiring capability for
self-sufficiency in growth signals 2. Insensitivity to anti-growth signals, 3. Evasion
of apoptotic cell death, 4. Acquiring capability for limitless replicative potential, 5.
Angiogenesis or the ability to form new blood vessels, and 6. Tissue invasion and
metastasis”.64
The conventional chemotherapy is the main treatment option available to the
cancer patients.65 Surgery and radiation therapy are two other most commonly used
treatment options for localized tumors.65 The drugs which are active against a cancer
of one tissue are reported to be mostly not effective against cancer of other tissues.66
Most of the chemotherapeutic drugs non-specifically target almost all dividing cells
and causes many toxic side-effects.67 They have very low therapeutic index. The
side-effects associated with cancer treatment as well as cost of treatment makes it a
dangerous disease. Selectively targeting cancer cells without inhibiting the normal
cells is an area of great interest in anti-cancer drug design.66 Very few cancers can be
completely cured.66 In most of the cases the goal of the treatment is to achieve
remissions and increase the survival rate of the patients.68 The rise of resistance to
the currently available drugs treatment is another major hurdle in cancer therapy.69,70
For many types of cancer we still need better treatment options.71 There is also
a wide variation in the global survival rate for different types of cancer. For example,
there is a considerable improvement in the five year survival rate in the case of
breast, colorectal and prostate cancer in developed nations.72 But for the same types
of cancer the survival rate is lower in developing or underdeveloped countries.72 The
five year survival rate for lung cancer patients in U.S.A is 15% only.73 The 5 year
survival rate for pancreatic cancer is less than 5%.74 Once the main line treatment
fails, currently there are no available drugs for some cancers like pancreatic cancer
10

and the five year survival rate is low.75 So there is an urgent need to discover new
compounds that could be developed as anti-cancer drugs. The newer approach in
cancer treatment is to target the altered cell survival pathways which are over
expressed in cancer cells.76 This approach is based on the assumption that targeting
over-expressed pathways will be more selective in destroying the cancer cells and
will have fewer effects on normal cells.76 Protein kinases which are important
constituents of cellular signal transduction pathways are frequently altered or
overexpressed in cancer cells.77,78 This has led to increased focus on kinases for
targeted anti-cancer drug discovery efforts.79,80

1.2.2 Protein Kinase
Protein kinases are critical components of cellular signal transduction
cascades.81 There are reported to be over 500 protein kinases in the human genome
and they are considered as the second largest group of drug targets.82,83 Kinases
catalyze the transfer of the terminal (or gamma) phosphate group of adenosine
triphosphate (ATP) to the specific hydroxyl group of serine, threonine, or tyrosine
residues in a protein substrate.84 This phosphorylation acts as a key event in signal
transduction and ultimately helps to transfer the signal from extracellular to
intracellular environment.84,85 The kinase mediated signal transduction plays a key
role in a number of important cellular processes like cell growth, cell differentiation,
maintaining cytoskeletal integrity and apoptosis.86 Hence aberrant kinase signaling
either from an activating mutation or over expression was reported to play a role in
diseases like cancer, inflammation, diabetes neurodegeneration and psoriasis.87 In
cancer cells, the kinase signaling pathways are often altered, resulting in
uncontrolled growth and increased capability to invade surrounding tissue.88 Agents
targeting altered kinase pathways are currently being developed as the next
generation anti-cancer agents. 89 , 90 Among different kinase signaling pathways,
altered or constitutively activated phosphoinositide 3-kinase (PI3K) pathway is
reported in many human cancers.91,92,93 Such aberrant PI3K pathway is implicated
in tumor development and progression and also in tumor’s response to cancer
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treatment. 94 3-Phosphoinositide-dependent protein kinase-1 (PDK1) is a pivotal
kinase for the PI3K pathway95 and is an attractive target for developing anticancer
therapeutics.96

1.2.3 3-Phosphoinositide dependent kinase-1 (PDK1)
PDK1 is a 63 kDa Serine/Threonine kinase and is ubiquitously expressed in
human tissues.97 It is a 556 amino acid containing enzyme.98 PDK1 possesses an
N-terminal kinase domain and C-terminal pleckstrin homology (PH) domain.98 PH
domain is involved in the interaction with the phosphatidyl-inositol 3,4,5
triphosphate (PtdIns(3,4,5)P3) in the membrane, and kinase domain is involved in
activation of other downstream kinases.99 PDK1 is noted as the master regulator of
cAMP-dependent, cGMP-dependent, protein kinase C (AGC) kinase family.100 It is
known to activate at least 23 downstream AGC kinases.101 These include protein
kinase B (PKB, also known as Akt),102,103 p70 ribosomal S6 kinase (S6K), 104
serum- and glucocorticoid-induced protein kinase (SGK)105and protein kinase C
(PKC) isoforms.106,107
X-ray crystal structures are available for PDK1 binding with its inhibitors in the
protein data bank (PDB).108,109,110,111 Like all other protein kinases, the catalytic
core of PDK1 has a bilobal domain, with predominantly α-helical C-terminal lobe
and an N-terminal lobe consisting mainly of β-sheets.108 The adenosine triphosphate
(ATP) binding region is located in the hinge region between the N- and C-terminal
lobes.108 As in other kinases, the ATP binding site in PDK1 can be divided into
adenine region, sugar region, and phosphate region.112 As PDK1 itself belongs to
the same AGC family as its substrates, it needs to be phosphorylated at the
activation loop or T-loop.100 PDK1 is reported to be constitutively active and has an
intrinsic ability to phosphorylate its own T-loop at Ser241 residue. 113 This
autophosphorylation is found to be mediated by intermolecular reaction.114 The
activation loop is a common feature in kinase superfamily.115 PDK1 kinase domain
has hydrophobic motif (HM) pocket or PDK1 interacting fragment (PIF) pocket.108
AGC kinases were reported to be activated by phosphorylation in two regions
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namely T-loop region and hydrophobic motif region.97 PDK1 is different from other
AGC kinases in that it does not have a separate hydrophobic motif.100 Studies have
shown that PDK1 is the major T-loop kinase of other AGC kinases.116
PDK1 function is reported to be regulated by substrate conformation and
sub-cellular location.95 The various kinases involved in PDK1 signaling pathway is
given in Figure 1.5. Activation of upstream PI3K leads to the synthesis of
phosphatidyl-inositol 3,4,5 triphosphate [PtdIns(3,4,5)P3]/ phosphatidyl-inositol 3,4
diphosphate [PtdIns(3,4)P2] at the plasma membrane.97 This results in PKB’s and
PDK1’s PH domain’s interaction with PtdIns(3,4,5)P3/PtdIns(3,4)P2 and thus causes
translocation to membrane and co-localization.99 The interaction of the PH domain
with PtdIns(3,4,5)P3 relieves autoinhibition of PKB and PDK1 phosphorylates PKB
on Thr308.95 Substrates other than PKB was reported to interact with PIF pocket of
PDK1 using their phosphorylated hydrophobic motif and then subsequently gets
activated by PDK1.117 Thus PDK1 acts as the sensor of substrate conformation and
is regulated by substrate conformation.

N - terminal lobe

ATP
T-Loop
Hinge Region

C – terminal lobe
Figure 1.4 Structure of PDK1 kinase domain with ATP molecule (PDB ID: 2BIY)101
13

PH

PI3K

AK T1

P

PDK -1

PTEN

PK Cz

P

S6 kinase

P

AK T1

PH

IKKβ
RSK

Pr otein synthesis
SGK

Sur vival
PtdIns(3,4,5)P3

I on tr anspor t

Figure 1.5 PDK1 signaling pathway
1.2.4 PDK1 as anti-cancer target
The tumor suppressor, Phosphatase and Tensin homologue deleted on
chromosome Ten (PTEN), acts as the phosphatidylinositol 3-phosphatase118 and
thus down regulates the PDK1-mediated growth and signaling pathway. Mutations
in PTEN resulting in elevated levels of PtdIns(3,4,5)P3 was reported in many human
cancers and in such cases inhibition of PDK1 is expected to mimic the tumor
suppressing activity of PTEN.119 Moreover, most of the downstream proteins of
PDK1 are also implicated in cancers.95,120,121,122,123 As PDK1 is the master regulator
of such AGC kinases, it is in a unique position to control all these proteins.
Accumulating pharmacologic and genetic evidences supports the potential role
of PDK1 as anticancer target.124,125 It has been reported that over-expression of
PDK1 in mammary cells resulted in their transformation in vitro and tumor
formation in vivo.125 Elevated levels of PDK1 phosphorylation was also reported in
metastasized breast tumors.126 Studies also showed that PDK1 phosphorylation is
associated with downstream kinase activation and together correlated with invasive
breast tumor.126 PDK1 is over-expressed in pre-malignant and low to high grade
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ovarian carcinomas.127 PDK1/AKT pathway is also reported to be activated in
Rhabdomyosarcoma (RMS).128 Targeting PDK1 with anti-sense oligonucleotides
has showed a marked reduction of cell proliferation and survival and also an
increased rate of apoptosis than that observed in PI3K or PKB inhibition.124 PDK1
was also reported as a potential target for sensitizing breast cancer cells to
chemotherapeutic agents. 129 Knock down of PDK1 was recently reported to
enhance the anti-tumor effect of EGFR inhibitor.130 These studies also show that
PDK1 inhibitors will help to improve the clinical response to EGFR inhibitors.
PDK1 is also reported to play a role in the motility of cancer cells.131 Lack of PDK1
is reported to cause inhibition of cell proliferation in mouse embryonic fibroblasts
(MEFs).132 A recent study shows that PDK1 mediates cell survival through another
distinct IκB kinase-β (IKKB)/NFkB pathway in addition to AKT pathway. 133
PDK1-hypomorphic mice which express only 10% of normal levels of PDK1 were
reported to be viable and fertile.134 This finding shows that inhibition of PDK1 can
be achieved without severe toxicity. A more recent study using PDK1-hypomorphic
mice has shown that the reduced PDK1 expression in PTEN+/- mice markedly
protected the animal from a wide range of tumors.135 Thus PDK1 has become a well
validated anticancer target. ATP competitive PDK1 inhibitors will compete with ATP
molecule to bind in the PDK1 active site and prevents the transfer of phosphate
group from ATP to downstream substrate proteins (Figure 1.6). This will result in the
blockade of PDK1 mediated signal transduction. Development of PDK1 inhibitor
could lead to development of better treatment options for cancer.
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Figure 1.6 Schematic diagram of PDK1 inhibitor action. PDK1 inhibitor block the
transfer of phosphate group from ATP molecule to substrate proteins

1.3 Overview of present work
Computational drug design approaches were reported to aid in the drug design
process. This approach helps to increase the efficiency of the drug discovery process
as well as reduce the experimental work done. We were interested to explore the
different aspects of computational drug design. As PDK1 is a well validated
anti-cancer target we selected it as our target molecule. The availability of X-ray
crystal structure of PDK1 allowed us to explore both the structure-based and
ligand-based drug design strategies.
Identification of correct binding mode is very essential for structure-based lead
optimization. Chapter 2 details our study of the binding mode of PDK1 with known
inhibitors including celecoxib and its derivatives using computational techniques
like molecular docking, molecular dynamics (MD) simulation, and molecular
mechanics-Poisson-Boltzmann surface area method (MM-PBSA). For celecoxib and
its derivatives, we had identified a new binding mode which serves as a better
starting point for structure-based drug design and further lead optimization of this
series.
Ligand-based drug design strategies can be explored to develop predictive
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3D-QSAR models as well as to understand the SAR for a given series. In Chapter 3,
our ligand-based study of PDK1 inhibitors belonging to the series of novel
indolinone derivatives was discussed. We have developed predictive 3D-QSAR
models

by

exploring

ligand-based

and

receptor-based

3D-QSAR

model

development strategies. Our models were internally and externally well validated. It
could be used in the further lead optimization of this series.
Chapter 4 details our work on virtual screening studies. We have developed a
novel hierarchical virtual screening strategy which combines ligand-based and
structure-based virtual screening. We have identified new hits in this process. One of
the compounds was found to have anti-cancer activity against many cancer cell lines
tested at national cancer institute (NCI) screening.

Copyright © Mohamed Diwan Mohideen AbdulHameed 2009
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CHAPTER 2

2. IDENTIFICATION OF NEW BINDING MODE AND ITS APPLICATION
IN LEAD OPTIMIZATION
Computational drug design strategies are utilized in both lead optimization and
lead identification processes. Lead optimization is the process by which a known
inhibitor (also called as the lead compound) of a particular target is used as the
starting point and further more potent inhibitors were developed. Computational
lead optimization strategies can adopt structure-based, ligand-based or combined
approaches. As discussed in the introduction, PDK1 is a well known anti-cancer
target and there is a need to develop new inhibitors for PDK1. This will help
towards the development of new anti-cancer drugs. In this chapter, we discuss the
application of structure-based lead optimization strategy against PDK1. Celecoxib
and its derivatives were used as the lead compounds and different sophisticated
computational approaches were utilized to understand the binding mode of these
inhibitors. The obtained binding mode serves as the starting point for further rational
design of new inhibitors. Part of the contents in chapter 2 was adapted from
published article, AbdulHameed et al. J. Phys. Chem. B. 2006, 110, 26365-26374.136

2.1 Celecoxib and its derivatives as lead molecules in PDK1 inhibitor design
Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor and used as a
non-steroidal

anti-inflammatory

drug

(NSAID).

137

It

is

a

well-known

FDA-approved drug in the market since 1998.137 Celecoxib (Commercial Name:
Celebrex; Company: Pfizer) is the first selective COX-2 inhibitor to be approved in
the market.138 It is approved for the treatment of osteoarthritis and rheumatoid
arthritis.139 Initial randomized clinical trials showed that the celecoxib produced
better anti-inflammatory activity than placebo.138 Clinical trials also showed that the
celecoxib was equivalent in efficacy as the conventional NSAIDs and produced less
gastrointestinal side-effects than traditional NSAIDs.138 The gastrointestinal ulcers
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and bleeding are some of the severe side effects of traditional NSAIDs.139 The
treatment of conditions like arthritis requires taking medications for a long time.
Hence side-effects like ulcers severely affect the patients, particularly the elderly
patients. Statistics shows that in United States alone, a total of ~16,000 patients with
arthritis died due to GI toxicity of NSAIDs during the year 1997.140 Nearly 200,000
to 400,000 hospitalizations were due to the GI complications of NSAID therapy.
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The cost of treating the GI complications due to NSAID therapy is around $0.8 to
1.6 billion/year in United States alone.141 Hence the discovery of selective COX-2
inhibitors was considered as a significant breakthrough in the treatment of
inflammatory conditions. The success of this class of drugs can be understood by the
fact that celecoxib is remembered as the fastest-selling drug in history.142 Despite
the unprecedented success of celecoxib in the market, stomach and intestinal ulcers
still occur with the use of celecoxib although the incidence is less than with other
NSAIDs in short-term studies.143 Further clinical trials showed that the increased
gastrointestinal protection of celecoxib is lost, when the patient is simultaneously
taking low-dose aspirin. 144 Moreover the therapeutic uses of selective COX-2
inhibitors were also limited by the occurrence of cardiovascular side-effects.145
Rofecoxib (brand name: Vioxx) is also a selective COX-2 inhibitor but was
withdrawn from the market due its cardiovascular effects.145 A boxed warning has
been added to the celecoxib label highlighting the potential of cardiovascular risk
associated with the use of this drug. 146 Researchers have identified that the
cardiovascular side-effect is not related to a particular drug but a class effect that
arises from the inhibition of cyclooxygenase pathway.147 Cyclooxygenase is a key
enzyme in the prostaglandin (PG) bio-synthesis pathway. By inhibiting COX-2, the
functions of all downstream PG synthases are blocked, including prostacyclin
synthase (PGIS) for the conversion of prostaglandin H2 (PGH2) to prostaglandin I2
(PGI2).139 PGI2 is reported to have a vasodilatory role.148 Blocking the production of
PGI2 has been reported to play a role in cardiovascular side effects.148 In addition to
the anti-inflammatory effect, celecoxib is in the spotlight for its anti-cancer activity.
Epidemiological studies have shown that the use of celecoxib and other NSAIDs
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were associated with a reduced risk of colon cancer.149 The use of celecoxib for
cancer prevention and treatment has become a very hot topic in the field of cancer
research. 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 Celecoxib was reported to cause significant
reduction in the number of colorectal polyps.158 It is the only NSAID that has been
approved for the familial adenomatous polyposis treatment.159 Overexpression of
COX-2 is reported in variety of malignancies.160 Inhibition of COX-2 by selective
inhibitors may account for the anti-carcinogenic activity of these compounds.137 But
there is a growing body of evidence to show the COX-2 independent anti-cancer
activity of NSAIDs. For example, studies have shown that celecoxib has apoptotic
effect which is independent of COX-2 inhibitory activity, 161 implying that the
well-known anticancer activity of celecoxib is not due to the inhibition of COX-2.
Different COX-2 inhibitors have the same ability to inhibit COX-2 but have
different apoptosis-inducing activity. 162 Celecoxib produces rapid induction of
apoptosis.162 Other potent COX-2 inhibitors like rofecoxib and DuP697 is reported
to have very low apoptosis inducing activity.162 This shows that the apoptosis
activity may be independent of COX-2 inhibitory activity. The cardio-vascular side
effect is considered as a class effect whereas the beneficial anti-cancer activity is not
considered as a class effect of coxibs.159 Experiments on the effect of selective
COX-2 inhibitors in COX-2 overexpressing (HCA-7) and COX-2 negative
(HCT-116) human colon cancer cells showed that only celecoxib has
anti-proliferative effect.159 This study showed that related coxibs like valdecoxib,
etoricoxib and rofecoxib has very weak or no anti-proliferative effects in vitro and in
vivo.159 Celecoxib is reported to produce similar apoptosis effect in BxPC-3
pancreatic carcinoma cell line which does not express COX-2 compared to
MIA-PaCA-2 cell line in which COX-2 is highly expressed.163 Studies have shown
that anti-sense mediated depletion of COX-2 did not produce apoptosis in prostate
cancer cells.161 It was also identified that the sensitivity of COX-2 inhibitor induced
apoptosis is independent of COX-2 expression.161 Further, a systematic
structure-activity relationship (SAR) study was performed to identify the functional
groups essential for apoptotic activity of celecoxib and similar compounds.162 In the
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work by Zhu et al. the molecule was divided into 3 regions and the structural
requirements for apoptosis inducing activity and COX-2 inhibition was explored.162
Through this detailed SAR analysis it was proved that the structural requirement for
apoptosis induction is different from COX-2 inhibitory activity. Another study has
shown that celecoxib inhibits PDK1 kinase activity.164 Zhu et al.165 demonstrated
that a series of celecoxib derivatives, through certain modification of the aryl group
and other groups of celecoxib, are more potent PDK1 inhibitors that have the desired
anticancer activity, but these celecoxib derivatives do not inhibit COX-2. Without
inhibiting COX-2, these compounds are not expected to have the common side
effects of the COX-2 inhibitors. Further structural modifications of celecoxib could
eventually lead to more potent PDK1 inhibitors as potentially more efficient
anticancer drugs that do not have the side effects of celecoxib. According to Zhu et
al.,165 celecoxib has an IC50 value of 48 µM, whereas a series of celecoxib
derivatives have IC50 values at the low micromolar, for inhibiting PDK1 kinase
activity.
To further develop a novel derivative of celecoxib with a lower IC50 value for
PDK1, one first needs to understand how celecoxib and its known derivatives bind
with PDK1. X-ray crystal structures are available for PDK1 binding with other
PDK1 inhibitors in the active site.108, 109, 110, 111 To begin a structure-based study, first
we have to understand the nature of the active site. As mentioned in chapter 1, the
catalytic core of PDK1 has a bilobal domain, with predominantly α-helical
C-terminal lobe and an N-terminal lobe consisting mainly of β-sheets.108 The
adenosine triphosphate (ATP) binding region is located in the hinge region between
the N- and C-terminal lobes.108 Based on the interaction of ATP, the ATP binding site
in kinase is usually divided into adenine region, sugar region, and phosphate
region.112 In PDK1, as in other kinases, adenine region consists of hydrophobic
residues and the adenine moiety also forms the conserved hydrogen bonds with the
backbone of hinge region.108 The sugar region is hydrophilic and consists of acidic
residues. The phosphate region is a solvent-exposed area.166 The ATP binding site of
PDK1 is shown in Figure 2.1
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ATP

Figure 2.1 The active site of PDK1 kinase domain with bound ATP molecule

By using the available X-ray crystal structures, Zhu et al.165 further proposed a
microscopic binding mode for PDK1 binding with celecoxib and its derivatives
based on some molecular docking tests with the compounds. Obviously, it is crucial
to know whether the proposed microscopic binding mode is reasonable or not for
future rational drug design targeting PDK1. A reasonable microscopic binding mode
for PDK1 binding with celecoxib and its derivatives could guide rational design of
significantly more potent PDK1 inhibitors. As discussed in the chapter 1, molecular
docking methods are now being routinely used to predict protein-ligand binding
modes.167 Some important shortcomings of the currently used docking programs are
associated with the difficulty of reliably accounting for the solvation/desolvation
effects on and entropic contributions to the protein-ligand binding.167 In addition, it
is also difficult to account for the effects of protein dynamics on the microscopic
binding during the simple docking process. Nevertheless, the protein-ligand binding
structures obtained from molecular docking can be considered as reasonable starting
structures for molecular dynamics (MD) simulations in water that can more
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reasonably account for the solvation effects and the dynamics of the protein-ligand
binding. Hence, in further considering the limit of traditional molecular docking
methods, we re-examined all of the possible microscopic binding modes for PDK1
binding with celecoxib and its derivatives (Figure 2.2), by using more sophisticated
computational

modeling

techniques,

including

molecular

dynamics

(MD)

simulations and molecular mechanics-Poisson-Boltzmann surface area (MM-PBSA)
calculations,168 in addition to the molecular docking. The MD simulations allow us
to obtain a dynamically stable protein-ligand binding mode associated with a stable
MD trajectory. Further, the MD simulations are followed by the MM-PBSA
calculations accounting for the contributions of the gas phase interactions, bulk
solvent, and entropy to the binding free energies. When a ligand has multiple
possible modes of binding with a protein, the relative binding free energies obtained
from the MM-PBSA calculations can be used to determine the most favorable
binding mode. The MD simulations followed by MM-PBSA calculations have been
used to accurately predict the protein-protein and protein-ligand binding free
energies for other systems.168,169
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Figure 2.2 Molecular structures of celecoxib and its representative derivatives.
In this study, molecular docking followed by MD simulations and MM-PBSA
binding free energy calculations has allowed us to examine various possible
microscopic binding modes for a given ligand with PDK1 and to theoretically
determine the most favorable binding mode, i.e. the one with the lowest binding free
energy. Thus, we have identified a new, more favorable binding mode for PDK1
binding with celecoxib and its derivatives. Based on the new binding mode, one can
better understand the available SAR data and the calculated binding free energies
were all in good agreement with available experimental activity data, providing
valuable new insights for future rational design of more potent PDK1 inhibitors.
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Figure 2.3 Molecular structures of staurosporine, BX-320, LY-333531, and BIM-1.

2.2 Computational Methods
2.2.1 Molecular docking
A few X-ray crystal structures are available for PDK1 binding with inhibitors
in the protein data bank (PDB). 170 The starting protein structure used for our
molecular docking is the X-ray crystal structure of ATP-bound PDK1 (pdb code:
2BIY),101 as this structure is more complete as compared with other X-ray crystal
structures of PDK1. The missing side chain atoms of residues Gln73, Arg75, Glu153,
Lys228, Arg238, Lys304, Glu343, Glu348, and Lys357 were modeled using Sybyl
7.0 program.171
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Molecular docking was carried out by using two different docking programs in
order to obtain different initial binding structures for MD simulations. One is FlexX
module of the Tripos software.172 The FlexX uses incremental docking algorithm
called pose clustering.172 In this program, the ligand molecule is split up into
fragments and the core fragment is first placed according to given scoring
function173 The molecule is built up using the tree search, which performs the
conformational search of the ligand and calculates its binding score.172 Only the best
conformation was built upon and the others are discarded. As discussed in the
introduction, the important steps in docking include generation of conformations,
placement in the active site and scoring the poses. FlexX uses MIMUMBA approach
for the generation of conformations and spherical interaction surfaces to model the
molecular interactions.48 The interaction type, interacting group and interacting
geometry were parameterized to account for interactions such as hydrogen bonds,
salt bridges, metal coordination, Π-Π interaction and hydrophobic interaction.48 The
“FlexX score” is used as the scoring function. FlexX score contains “a hydrogen
bonding term, a penalty for protein-ligand overlap, a pairwise hydrophobic potential
and additional terms for hydrophobic contacts”.48 The receptor description file for
our docking with the FlexX module was built upon using the PDK1 structure110 and
the residues within 5 Å around the ligand were defined as the active site. The
docking was performed for four representative ligands, i.e. celecoxib and its three
representative derivatives depicted in Figure 2.2, with different IC50 values for
PDK1. The molecular structures of these ligands were drawn and energy-minimized
by using the Sybyl 7.0 program with the Tripos force field.174 For docking with
each ligand, 30 poses were saved for further examination before the best possible
poses were chosen based on the docking scores.
The other program used in our molecular docking is DOCK,175,176,177 which
uses incremental construction algorithm for flexible docking.178 We also used the
DOCK program because a previously reported binding mode165 could not be
obtained from the molecular docking using the FlexX for some protein-ligand
binding systems. The DOCK program was used only in these special cases. The
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ligand orientations were scored through the use of a force field-based energy scoring
function and the top-scored binding structure was selected. Both the FlexX and
DOCK programs use incremental docking algorithm for flexible docking of ligands.
The major difference is that whereas the FlexX program uses an empirical scoring
function based on the work of Bohm179 and Klebe,180 the DOCK program uses a
grid-based energy scoring function.181 In the DOCK approach, the binding site is
filled with spheres and the center of each sphere was used as a matching point to
guide the orientation of ligand in the active site.182 DOCK uses Anchor and Grow
algorithm for incremental construction of the ligands in the active site.182 The files
of protein and ligands required for using the DOCK 5.2 program were prepared by
using Sybyl 7.0. The active site spheres were prepared using SPHGEN program.183
The spheres were selected such that they cover the entire ligand-binding region.
These spheres served to orient ligands in the active site.183 Grid calculations were
carried out by using 0.3 Å grid spacing.

2.2.2 Molecular dynamics
The possible protein-ligand binding complexes obtained from the molecular
docking with the ligands depicted in Figure 2.2 were used as the initial structures for
MD simulations. Besides, we also examined other four ligands that have X-ray
crystal structures available for their binding with PDK1, i.e. Staurosporine (pdb code:
1OKY),110 BX-320 (pdb code: 1Z5M),111 LY-333531 (pdb code: 1UU8),109 and
BIM-1 (pdb code: 1UU3),109 and carried out MD simulations on these four
protein-ligand complexes. The residues #230 to #241 were missing in these
structures. To complete the protein structures for these four complexes, each of these
four incomplete X-ray crystal structures were superimposed with the complete
protein structure constructed from the structure in 2BIY. Thus we obtained the
complete protein structure binding with Staurosporine, BX-320, LY-333531, and
BIM-1. These complete complex structures were also used as the initial structures
for MD simulations.
The MD simulations were performed using Sander module of Amber 8
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program.184 The partial atomic charges for the ligand atoms were calculated using
the RESP protocol185 after electrostatic potential calculations at Hartree-Fock (HF)
level with 6-31G* basis set using Gaussian 03 program. 186 Each PDK1-ligand
binding complex was neutralized by adding counterions (three Cl- ions) and was
solvated in a rectangular box of TIP3P water molecules187 with a minimum solute
wall distance of 10 Å. The solvated systems were carefully equilibrated and fully
energy-minimized. These systems were gradually heated from T = 10 K to T =
298.15 K in 35 ps before a production MD simulation run for 1 ns, or longer, until a
stable MD trajectory was obtained for each of the simulated systems. The time step
used for the MD simulations was 2 fs. Periodic boundary conditions in the NPT
ensemble at T = 298.15 K with Berendsen temperature coupling188 and P = 1 atm
with isotropic molecule-based scaling185 were applied. The SHAKE algorithm189
was used to fix all covalent bonds containing hydrogen atoms. The non-bonded pair
list was updated every 10 steps. The particle mesh Ewald (PME) method190 was
used to treat long-range electrostatic interactions. Restrain was placed on the
C-alpha backbone atoms during the MD run. A residue-based cutoff of 12 Å was
utilized for the non-covalent interactions. The time-dependent geometric parameters
were carefully examined to make sure that we obtained a stable MD trajectory for
each simulated protein-ligand binding system. The coordinates of the simulated
system were collected every 1 ps during the simulation. The equally distributed 100
snapshots of the simulated structure within the stable MD trajectory were used to
perform the MM-PBSA calculations.

2.2.3 Binding free energy calculation
The binding free energies were calculated by using the molecular
mechanics-Poisson-Boltzmann surface area (MM-PBSA) free energy calculation
method.168

In

the

MM-PBSA

method,

the

free

energy

of

the

receptor/protein-inhibitor binding, ∆G bind, is obtained from the difference between
the free energies of the receptor/protein-ligand complex (Gcpx) and the unbound
receptor/protein (Grec) and ligand (Glig) as following:
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∆Gbind = Gcpx - Grec – Glig

(2-1)

The binding free energy (∆Gbind) was evaluated as a sum of the changes in the
molecular mechanical (MM) gas-phase binding energy (∆EMM), solvation free
energy (∆Gsolv), and entropic contribution (-T∆S):
∆Gbind = ∆Ebind - T∆S

(2-2)

∆Ebind = ∆EMM + ∆Gsol

(2-3)

∆EMM = ∆Eele + ∆Evdw

(2-4)

∆Gsol = ∆GPB + ∆Gnp

(2-5)

∆Gnp = γ*SASA + β

(2-6)

The MM binding energies were calculated with the ANAL module of Amber8
program. Electrostatic solvation free energy was calculated by the finite-difference
solution to the Poisson–Boltzmann equation (∆GPB) as implemented in the Delphi
program. 191,192 Used in the solvation calculation was a grid spacing of 0.5 Å,
80%-filled grid box, an exterior dielectric constant of 80, and an interior dielectric
constant of 1. Parse radius 193 and Amber charge 194 were used in the Delphi
calculations. The radius used for the solvent probe is 1.4 Å. The MSMS program195
was used to calculate the SASA for the estimation of the non-polar solvation energy
(∆Gnp) using Eq.(2-6) with the default parameters, i.e. γ = 0.00542 kcal/Å 2 and β =
0.92 kcal/mol. Further, the entropic contribution, -T∆S, to the binding free energy
was also calculated at T = 298.15 K by using the NMODE module of Amber8
program which is based on a combination of the standard classical statistical
formulas196 and normal mode analysis.197
The final ΔEMM and ΔGsol values for each protein-ligand binding mode were
taken as the averages of the respective ΔEMM and ΔGsol values calculated for the 100
snapshots. For these energetic calculations, the ligand and the receptor were studied
using the snapshots from the complex simulation (without performing further energy
minimization); the water molecules and counter ions were stripped away before
MM-PBSA analysis. To evaluate –TΔS, a full energy minimization was first
performed on each species (receptor, ligand, or complex) prior to the normal mode
analysis. As the full energy minimization and normal mode analysis are much more
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time-consuming than the single-point energy calculations, we only evaluated the
–TΔS values for 10 of the above 100 snapshots (i.e. one from each 10 of the above
100 snapshots). The final -TΔS value for each protein-ligand binding mode was
taken as the average of the -TΔS values calculated for the 10 snapshots.

2.3 Validation study and identification of new binding mode
2.3.1 Binding with staurosporine, BX-320, LY-333531, and BIM-1.
X-ray crystal structures have been reported for PDK1 binding with some PDK1
inhibitors, including staurosporine, BX-320, LY-333531, and BIM-1 depicted in
Figure 2.3. Through MD simulations and MM-PBSA calculations on PDK1 binding
with these four inhibitors whose binding modes have been known in the X-ray
crystal structures, we tested whether the computational protocol used in this study,
i.e. MD simulations followed by MM-PBSA calculations, can reasonably predict the
PDK1-ligand binding free energy for a given binding mode.
The MD simulation for each of the PDK1-ligand binding structures was quickly
stabilized, because there was no any significant structural change during the
simulation (see Figure 2.5 for the MD trajectories). The MD-simulated PDK1-ligand
binding structures (Figure 2.4) were all essentially the same as the corresponding
X-ray crystal structures. We did not note any significant difference between the
MD-simulated structures and the corresponding X-ray crystal structures. The
energetic results obtained from the MM-PBSA calculations for these binding
structures are summarized in Table 2.1, in comparison with available experimental
data. As seen in Table 2.1, the calculated binding free energies (∆Gbind) were all in
good agreement with the corresponding experimental ∆Gbind values (derived from
the experimental IC50 values reported in literature); the average absolute deviation is
~1.2 kcal/mol. More importantly, the qualitative order of the calculated ∆Gbind
values was completely consistent with that of the experimental ∆Gbind values. The
reasonable agreement between the calculated and experimental binding free energies
showed that the computational protocol was adequate for predicting PDK1 binding
with its ligands.
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(A)

(B)
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(C)

(D)

Figure 2.4 MD-simulated structures of PDK1 binding with (A) staurosporine, (B)
BX-320, (C) LY-333531, and (D) BIM-1.
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Figure 2.5 Plots of MD-simulated internuclear distances versus simulation time for
PDK1 binding with staurosporine, BX-320, LY-333531, and BIM-1 (see Figure 2.3
for the structures and the positions of atoms referred here). (A) staurosporine: D1
refers to the distance between O3 atom of Staurosporine and the NH hydrogen of
Ala162 backbone, D2 the distance between H19 atom of staurosporine and the
carbonyl oxygen of Ser160 backbone, and D3 the distance between H9 atom of
staurosporine and the carbonyl oxygen of Glu209 backbone. (B) BX-320: D1 refers
to the distance between H29 atom of BX-320 and the carbonyl oxygen of Ala162
backbone, D2 the distance between N2 atom of BX-320 and the NH hydrogen of
Ala162 backbone, and D3 the distance between O1 atom of BX-320 and the NH
nitrogen atom of Glu166 backbone. (C) LY-333531: D1 refers to the distance
between O2 atom of LY-333531 and the NH hydrogen of Ala162 backbone, D2 the
distance between H10 atom of LY-333531 and the carbonyl oxygen of Ser160
backbone, and D3 the distance between O1 atom of LY-333531 and the hydroxyl
hydrogen of Thr222 side chain. (D) BIM-1: D1 refers to the distance between O2
atom of BIM-1 and the NH hydrogen of Ala162 backbone, D2 the distance between
H18 atom of BIM-1 and the oxygen atom of Ser160 backbone carbonyl group, and
D3 the distance between O1 atom of BIM-1 and the hydroxyl hydrogen of Thr222
side chain.
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Table 2.1 Binding free energies (kcal/mol) calculated at T = 298.15 K and P = 1 atm
for PDK1 binding with representative inhibitors in comparison with the
corresponding experimental data.136
Calc.a

Inhibitor
Staurosporine
BX-320
LY-333531
BIM-1
a

ΔEMM
-93.8 (1.4)
-127.5 (2.1)
-107.7 (1.4)
-82.8 (1.4)

ΔGsol
60.3 (1.3)
97.3 (2.2)
77.4 (1.6)
59.0 (1.8)

-TΔS
∆Gbind
21.7 (2.5) -11.8 (1.9)
18.7 (1.9) -11.5 (2.1)
20.1 (1.9) -10.2 (1.8)
16.1 (2.4) -7.7 (2.1)

Expt.b
∆Gbind
-11.2
-10.1
-8.4
-6.9

The MM-PBSA calculations were performed on 100 snapshots along a stable MD

trajectory for each PDK1-inhibitor binding complex. The results given in the table
are the average values calculated for the 100 snapshots.
b

Experimental binding free energies were calculated from the experimental IC50

values reported in refs.109, 110 and 111 via ΔGbind = RT × lnKd ≈ RT × lnIC50.

2.3.2 Binding with celecoxib and its derivatives
To understand how PDK1 binds with celecoxib and its derivatives, four
representative compounds (depicted in Figure 2.2) were considered whose
experimental IC50 values for inhibiting PDK1 kinase activity range from 48 µM to 5
µM. The molecular docking revealed two quite different possible binding modes for
each of these compounds binding with PDK1 and the scores are given in Table 2.2.
For all the compounds FlexX gave a new binding mode. DOCK results showed only
the mode which was similar to that proposed by Zhu et al.165 Further MD
simulations led to a stable MD trajectory, as seen in Figure 2.10 to 2.13, for each of
the binding modes (Figures 2.6 to 2.9). So, we could not simply judge which binding
mode is more reasonable without further evaluating the relative binding free
energies.
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(A)

(B)

Figure 2.6 MD-simulated structures of PDK1 binding with celecoxib: (A) new
binding mode determined in our work (ref. 136); (B) the binding mode similar to
that proposed by Zhu et al. (ref.165).
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(A)

(B)

Figure 2.7 MD-simulated structures of PDK1 binding with celecoxib-der1: (A) new
binding mode determined in our work (ref. 136); (B) the binding mode similar to
that proposed by Zhu et al. (ref. 165).
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(A)

(B)

Figure 2.8 MD-simulated structures of PDK1 binding with celecoxib-der2: (A) new
binding mode determined in our work (ref. 136); (B) the binding mode similar to
that proposed by Zhu et al. (ref. 165).
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(A)

(B)

Figure 2.9 MD-simulated structures of PDK1 binding with celecoxib-der3: (A) new
binding mode determined in our work (ref.136); (B) the binding mode similar to that
proposed by Zhu et al. (ref. 165).
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Figure 2.10 Plots of MD-simulated internuclear distances and RMSD for atomic
positions of the ligand versus simulation time for PDK1 binding with celecoxib-der1
(see Figure 2.2 for the structure). (A) The new binding mode determined in our work
for the first time (ref. 136): D1 refers to the distance between N1 atom of
celecoxib-der1 and one of the two oxygen atoms of Asp223 side chain carboxyl
group, D2 the distance between N4 atom of celecoxib-der1 and the nitrogen atom of
Lys111 side chain, and D3 the distance between N4 atom of celecoxib-der1 and the
nitrogen atom of Asp223 backbone. (B) The binding mode similar to that proposed
by Zhu et al. (ref. 165): D1 refers to the distance between O1 atom of
celecoxib-der1 and the hydroxyl oxygen of Thr222 side chain, D2 the distance
between N1 atom of celecoxib-der1 and the carbonyl oxygen of Ser160 backbone,
and D3 the distance between N4 atom of celecoxib-der1 and the nitrogen atom of
Glu166 backbone.
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Figure 2.11 Plots of MD-simulated internuclear distances and RMSD for atomic
positions of the ligand versus simulation time for PDK1 binding with celecoxib (see
Figure 2.2 for the structure). (A) The new binding mode determined in our work for
the first time (ref. 136): D1 refers to the distance between N2 atom of celecoxib and
the carbonyl oxygen of Glu209 backbone, D2 the distance between N3 atom of
celecoxib and the NH nitrogen of Asp223 backbone, and D3 the distance between
N3 atom of celecoxib and the nitrogen atom of Lys111 side chain. (B) The binding
mode similar to that proposed by Zhu et al. (ref. 165): D1 refers to the distance
between O1 atom of celecoxib and the hydroxyl oxygen of Thr222 side chain, D2
the distance between N3 atom of celecoxib and the NH nitrogen of Glu166
backbone, and D3 the distance between N3 atom of celecoxib and the carbonyl
oxygen of Ala162 backbone.
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Figure 2.12 Plots of MD-simulated internuclear distances and RMSD for atomic
positions of the ligand versus simulation time for PDK1 binding with celecoxib-der2
(see Figure 2.2 for the structure). (A) The new binding mode determined in our work
for the first time (ref. 136): D1 refers to the distance between N2 atom of
celecoxib-der2 and the carbonyl oxygen of Glu209 backbone, D2 the distance
between N2 atom of celecoxib-der2 and one of the two oxygen atoms of Asp223
side chain carboxyl group, D3 the distance between O2 atom of celecoxib-der2 and
the nitrogen atom of Asn210 backbone, and D4 the distance between N3 atom of
celecoxib-der2 and the nitrogen atom of Asp223 backbone. (B) The binding mode
similar to that proposed by Zhu et al. (ref. 165): D1 refers to the distance between
N2 atom of celecoxib-der2 and the nitrogen atom of Ala162 backbone, D2 the
distance between N2 atom of celecoxib-der2 and the carbonyl oxygen of Ser160
backbone, and D3 the distance between O2 atom of celecoxib-der2 and the hydroxyl
oxygen of Thr222 side chain.
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Figure 2.13 Plots of MD-simulated internuclear distances and RMSD for atomic
positions of the ligand versus simulation time for PDK1 binding with celecoxib-der3
(see Figure 2.1 for the structure). (A) The new binding mode determined in our work
for the first time (ref. 136): D1 refers to the distance between N1 atom of
celecoxib-der3 and the nitrogen atom of Asp223 backbone, D2 the distance between
N3 atom of celecoxib-der3 and the carbonyl oxygen of Glu90 backbone, and D3 the
distance between N4 atom of celecoxib-der3 and the carbonyl oxygen atom of
Glu90 backbone. (B) The binding mode similar to that proposed by Zhu et al. (ref.
165): D1 refers to the distance between N3 atom of celecoxib-der3 and the carbonyl
oxygen of Ala162 backbone, D2 the distance between N4 atom of celecoxib-der3
and the nitrogen atom of Ala162 backbone, and D3 the distance between N1 atom of
celecoxib-der3 and the nitrogen atom of Glu166 backbone.
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Based on the molecular docking followed by the MD simulations, one of the
two possible binding modes (see mode “B” depicted in Figures 2.6 to 2.9) is similar
to that proposed by Zhu et al.165 For a remarkable feature of this binding mode, the
4-methyl-phenyl group of celecoxib (or the phenanthrene ring of the celecoxib
derivatives) was positioned in the ATP sugar/phosphate binding region formed by
Gly89, Glu90, Gly91, and Ser94 residues. This hydrophilic environment looks more
appropriate to accommodate a hydrophilic functional group of a ligand. The only
hydrophobic residue nearby the 4-methyl-phenyl group of celecoxib is Val96 at a
distance >3.5 Å. Glu166 is close to both the pyrazole ring and 4-methyl-phenyl of
celecoxib. The other binding mode (see mode “A” depicted in Figure 2.6) found in
our docking and MD simulations for the first time is totally different. In this newly
found binding mode, the 4-methyl-phenyl moiety of celecoxib stays in the adenine
pocket and is sandwiched between the hydrophobic residues Val96 and Leu212, the
sulfonamide moiety extends into the sugar/phosphate pocket and forms a hydrogen
bond with the carbonyl oxygen of Glu209 backbone, and a nitrogen on the pyrazole
ring forms a hydrogen bond with the protonated amine group on the Lys111 side
chain. This binding mode allows the CF3 group to stay in a small hydrophobic
pocket defined by residues Leu159, Phe157, Leu113, Met134, and Val143. The
conserved residues Lys111 and Glu130 are nearby this small pocket. Further, all the
celecoxib derivatives examined in this study bind with PDK1 in a similar way as
celecoxib, as seen in Figures 2.6 to 2.9. For example, when the 4-methyl-phenyl
group of celecoxib is replaced by a phenanthrene ring, celecoxib becomes
celecoxib-der2 (see Figure 2.2) and the phenanthrene ring of celecoxib-der2 also
stays in the adenine pocket although the phenanthrene ring is surrounded by more
hydrophobic residues (including Leu88 in addition to Val96 and Leu212). An
interesting difference is that the terminal sulfonamide group of this derivative forms
a hydrogen bond with Asp223, instead of Glu209, for the binding with celecoxib.
The celecoxib-der1 and celecoxib-der3 retain the same hydrophobic interactions
between the phenanthrene ring and the adenine pocket as that found in
celecoxib-der2 binding with PDK1. These derivatives show flexibility in their
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interactions with the sugar/phosphate pocket. The amino group of celecoxib-der3
forms a hydrogen bond with the carbonyl oxygen of Glu90 backbone, whereas
celecoxib-der1 does not have such a strong hydrogen bond with PDK1.
MM-PBSA calculations were performed to calculate the binding free energies
for all of the MD-simulated binding structures and the calculated binding free
energies are summarized in Table 2.2. We note that the binding free energy for a
given binding mode is determined by all of the contributions from the protein-ligand
interactions in the gas phase, solvation/desolvation effects, and entropy change. In
comparison between the two different modes of PDK1 binding with a given ligand
(i.e. celecoxib or its derivative), one binding mode might be much more favorable
than the other in the gas phase, but the solvation/desolvation effects could make a
big difference in changing the relative binding free energies. As seen in Table 2.2,
for each of these compounds binding with PDK1, the binding free energy calculated
for our newly found binding mode is always significantly lower than that calculated
for the other binding mode (similar to that proposed by Zhu et al.165), which
suggests that our newly found binding mode is significantly more favorable.
According to the new binding mode, the binding free energies calculated for PDK1
binding with all of these compounds are reasonably close to the corresponding
experimental binding free energies (derived from the experimental IC50 values
reported by Zhu et al.165); the average absolute deviation is ~0.9 kcal/mol. This
agreement further supports that the new binding mode found for PDK1 binding with
celecoxib and its derivatives in this study is more reasonable.
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Table 2.2 Binding free energies (kcal/mol) calculated at T = 298.15 K and P = 1 atm
for PDK1 binding with celecoxib and its derivatives (der1, der2, and der3) in
comparison with the corresponding experimental data.a,136
Compound
Celecoxib

Celecoxib-der1

Binding
mode
This workb

Docking
scoring d
-3.1

Zhu et al.c

(-43.8)

This workb

-4.9

Zhu et al.c

(-47.9)

Celecoxib-der2
This workb
(i.e. OSU-02067)
Zhu et al.c
Celecoxib-der3
This workb
(i.e. OSU-03012)
Zhu et al.c

-5.6
(-49.4)
-6.5
-4.4

ΔEMM
-56.5
(1.7)
-59.1
(1.4)
-71.2
(2.0)
-61.0
(3.1)
-64.6
(1.7)
-71.5
(1.7)
-96.8
(2.9)
-48.2
(1.9)

MM-PBSAe
ΔGsol
-TΔS
40.1
11.3
(1.6)
(0.2)
48.5
11.0
(1.6)
(1.9)
54.8
11.9
(2.0)
(1.2)
50.9
13.2
(1.5)
(1.3)
45.1
12.1
(1.4)
(2.0)
55.6
11.8
(1.5)
(1.5)
78.0
12.6
(2.8)
(2.0)
45.9
12.1
(2.5)
(0.8)

a

All energies are in kcal/mol.

b

The new binding mode determined in our study (ref. 136).

c

The binding mode reported by Zhu et al. (ref. 165).

d

∆Gbind
-5.1
(1.1)
0.4
(1.6)
-4.5
(1.6)
3.1
(1.9)
-7.3
(1.7)
-3.7
(1.4)
-6.2
(2.0)
9.8
(1.4)

Expt.f
∆Gbind
-5.9

Scores of the molecular docking using the FlexX program. The values in

parentheses are scores of the molecular docking using the DOCK program; the
DOCK program was used for these binding structures because the molecular
docking using the FlexX program did not reveal these binding structures. We note
that the DOCK score is the gas phase interaction energy which does not account for
the solvation. Thus, the two types of docking scores cannot be compared.
e

The MM-PBSA calculations were performed on 100 snapshots along a stable MD

trajectory for each PDK1-inhibitor binding mode. The results given in the table are
the average values calculated for the 100 snapshots. The values in the parentheses
are the root-mean-square fluctuations of the calculated energies.
f

Experimental binding free energies are calculated from IC50 (ref 165) via ΔGbind =
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-6.0

-6.9

-7.2

RT lnKd ≈ RT lnIC50.

2.3.3 Significance of new binding mode
Further, the new, more favorable binding mode found in this study can help to
better understand the substituent effects of the celecoxib derivatives on the
previously reported biological activity. 165,162 For example, some experimental trends
can be understood easily now when we know that the 4-methyl-phenyl group of
celecoxib stays in the hydrophobic adenine pocket. When the 4-methyl-phenyl group
of celecoxib is replaced by a phenanthrene group, celecoxib becomes celecoxib-der2
and the IC50 value changes from 48 μM to 9 μM.165 The activity increase from
celecoxib to celecoxib-der2 is attributed to the increase of the size of the
hydrophobic functional group (from the 4-methyl-phenyl to phenanthrene)
interacting with the hydrophobic adenine pocket of PDK1. So, the hydrophobic
interaction for PDK1 binding with celecoxib-der2 should be stronger than that with
celecoxib. The additional interaction of celecoxib-der2 with Leu88 residue is shown
in Figure 2.14. When 4-methyl-phenyl group of celecoxib is replaced by
4-amino-phenyl group, the hydrophobic interaction is expected to decrease and,
therefore, its binding affinity with PDK1 is expected to decrease, which is consistent
with the experimental observation of the decrease in the apoptotic activity.162 The
molecular structures of celecoxib-der1 and celecoxib-der3 differ only by a -CH2group, but show a significant difference in the IC50 value (40 μM for celecoxib-der1
versus 5 μM for celecoxib-der3), as seen in Figure 2.2. According to our newly
found binding mode, the amino group of celecoxib-der3 forms a hydrogen bond
with the carbonyl oxygen of Glu90 backbone, whereas the similar hydrogen bonding
does not exist in celecoxib-der1 binding with PDK1 (Figure 2.15). The difference in
the hydrogen bonding reveals that celecoxib-der3 binds with PDK1 stronger than
celecoxib-der1 with PDK1, which explains why the IC50 value of celecoxib-der3 is
significantly lower than that of celecoxib-der1. Previously reported SAR studies by
Zhu et al.162 identified that CF3 group, tolyl group and sulfonamide group of
celecoxib are essential for its apoptosis activity. Removal of CF3 group was reported
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to produce a loss of apoptosis activity of celecoxib. In our newly proposed binding
mode, as seen in Figure 2.16, the CF3 group occupies a small hydrophobic pocket
defined by residues Leu159, Phe157, Leu113, Met134, and Val143. The tolyl group
occupies the hydrophobic adenine pocket and the sulfonamide group has interaction
in the sugar binding region. We also analyzed whether our newly proposed binding
mode can explain the difference in apoptotic activity between celecoxib and
rofecoxib. In the case of Rofecoxib, the furanone ring will have unfavorable
interaction with the hydrophobic residues (Figure 2.16). Due to the absence of
sulfonamide group, there is a loss of hydrogen bonding interaction which is
observed in celecoxib in sugar pocket. This explains the loss of apoptotic activity for
rofecoxib.
Another interesting aspect in our newly proposed binding mode is the absence
of hydrogen bonding interaction with the hinge region. To the best of our knowledge,
we have identified for the first time a new binding mode of kinase inhibitor without
hinge hydrogen bonding interaction. A recent review by Liu et al. in 2006 reports
that almost all kinase inhibitors has a hydrogen bond interaction with the hinge
region.198 Our newly proposed binding mode will serve as a good starting point for
the design of new class of PDK1 inhibitors without hinge hydrogen bonding region.
Further experimental tests are needed to analyze whether binding without hinge
hydrogen bond interactions confers selectivity for the inhibitors. More recently, after
publication of our result, an X-ray crystal structure of cyclin-dependent kinase-2
(CDK2) with inhibitor was deposited in PDB (PDB ID: 2UZD).199 Richardson et al.
shows that the new class inhibitors interact with CDK2 without hinge hydrogen
bond interaction (Figure 2.17).199 This X-ray crystal structure further serves as an
experimental proof for design of inhibitors without hinge hydrogen bond interaction
and it is consistent with our newly proposed binding mode for celecoxib and its
derivatives.
Our newly proposed binding mode serves as the starting point for further
optimization of this series. De novo drug design of new inhibitors can be carried out
based on the study of the binding mode and the environment around the inhibitors.
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Based on our initial study, we propose that the celecoxib and its derivatives could be
modified in two regions as shown in Figure 2.18. Additional interactions could be
introduced through substitution of suitable groups either in hinge region or in sugar
binding region or both. In kinase inhibitor design, a small hydrophobic pocket deep
inside the active site has been exploited for achieving potency and selectivity.79
“Gate-keeper” is the term used to denote the residues which are present at the
entrance of the hydrophobic pocket in kinases. A small gate-keeper residue like
threonine has been reported to allow bulky groups to enter the hydrophobic pocket
whereas larger gate-keeper residues like phenylalanine restrict access to this
pocket.200 In the case of PDK1, Leu159 is present as the gate-keeper residue. In our
newly found binding mode, the CF3 group of celecoxib and its derivatives occupies
the hydrophobic pocket. We propose that further studies involving isosteric
replacement of CF3 group with methyl or iodide groups will help to understand the
significance of interaction of this group. Studies using X-ray crystallography or
point mutations would also help to further confirm the new binding mode
experimentally.
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(A)
Val96
Leu159

Leu212
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Leu88

Leu159

Leu212

Figure 2.14 PDK1 binding with celecoxib and celecoxib-der2 in the newly
identified binding mode. PDK1 binding with (A) celecoxib and (B) celecoxib-der2.
The violet dotted lines show hydrophobic contacts.
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(A)

(B)

Figure 2.15 PDK1 binding with inhibitors in the newly identified binding mode.
PDK1 binding with (A) celecoxib-der1 and (B) celecoxib-der3. The violet dotted
lines show hydrophobic contacts.
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Figure 2.16 Schematic diagram showing PDK1 binding with inhibitors in the newly
identified binding mode. PDK1 binding with (A) celecoxib and (B) rofecoxib.
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Figure 2.17 CDK2 binding with inhibitor without hinge hydrogen bond interaction
(PDB ID: 2UZD).199

2.4 Summary of main computational insights
Extensive molecular docking and combined molecular dynamics (MD)
simulations and molecular mechanics-Poisson-Boltzmann surface area (MM-PBSA)
binding free energy calculations have demonstrated a new, more favorable
microscopic binding mode concerning how celecoxib and its derivatives bind with
3-Phosphoinositide-dependent protein kinase-1 (PDK1). The new binding mode was
remarkably different from that proposed previously based on simple molecular
docking tests. For example, the 4-methyl-phenyl moiety of celecoxib stays in the
hydrophobic adenine pocket and is sandwiched between the hydrophobic residues
Val96 and Leu212 according to the new binding mode, whereas the 4-methyl-phenyl
moiety is positioned in the ATP sugar/phosphate binding region (which is
hydrophilic) according to the previously proposed binding mode. For celecoxib and
all of the derivatives binding with PDK1, the binding free energies determined for
the new binding mode by the combined MD simulations and MM-PBSA
calculations were always significantly lower than those determined for the
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previously proposed binding mode. So the new binding was energetically more
favorable. Thus we have identified a totally new binding mode for the first time.
This binding mode can be used for further de novo design of novel PDK1 inhibitors.

Figure 2.18 PDK1 binding with celecoxib in the newly identified binding mode.
Potential region for de novo design are marked in red circle.

For all of the representative PDK1 inhibitors examined in this study, based on
the most favorable binding modes, the calculated binding free energies were all in
good agreement with the corresponding experimental activity data. All of the
computational results reported in this study strongly suggest that (1) the new
microscopic binding mode determined in this work is reliable; (2) the determined
new, more favorable binding mode can help to better understand the substituent
effects of the celecoxib derivatives on the previously reported biological activity
data; and (3) the computational protocol tested in this study, i.e. the molecular
docking followed by the combined MD simulations and MM-PBSA calculations, is
reliable and accurate for predicting protein-ligand binding structures and binding
free energies, whereas only performing simple molecular docking could lead to a
54

wrong binding mode and thus mislead the drug design. These new insights will be
valuable not only for future rational design of novel, more potent PDK1-specific
inhibitors as promising anticancer therapeutics, but also for rational design of drugs
targeting other proteins.

Copyright © Mohamed Diwan Mohideen AbdulHameed 2009
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CHAPTER 3
3. LIGAND-BASED DRUG DESIGN: DEVELOPMENT OF PREDICTIVE
3D-QSAR MODELS
Computational lead optimization strategies can adopt structure-based,
ligand-based or combined approaches. PDK1 is a well known anti-cancer target and
application of such computational drug design approaches will help towards the
development of potent PDK1 inhibitors and ultimately lead to development of
anti-cancer agents. In the previous chapter, we discussed the application of
computational structure-based lead optimization strategy against PDK1. We used
celecoxib and its derivatives as the lead compounds and identified the binding mode
of these inhibitors which serves as the starting point for further rational design of
new inhibitors. In this chapter, we discuss the application of ligand-based lead
optimization strategy and combined approaches against PDK1. Part of the contents
in chapter 3 was adapted from published article, AbdulHameed et al. J. Chem. Inf.
Mol. Mod. 2008, 48, 1760-1772.201
3.1 Ligand-based modeling study on indolinone derivatives as PDK1 inhibitors
Computational approaches like structure-based and ligand-based ones have been
found to be valuable in further optimization and development of novel inhibitors.
Ligand-based
(3D-QSAR)

three-dimensional
approaches,

quantitative

including

structure-activity

comparative

molecular

relationship

field

analysis

(CoMFA)202 and comparative molecular similarity indices analysis (CoMSIA),203
were reported to be effective for understanding the structure-activity relationships.37
The 3D-QSAR modeling is useful to predict the activity of new molecules to be
synthesized.37 3D-QSAR methods serve as an important complement to the
structure-based methods.37 CoMFA and CoMSIA are two 3D-QSAR methods that
have been successfully employed in drug design.204,205 These methods were useful
in

the

lead

optimization

and

also
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in

understanding

the

drug-target

interaction.206,207,208 In CoMFA, the biological activity of molecules is correlated
with their steric and electrostatic interaction energies.209 The steric and electrostatic
interaction energies are calculated using Lennard-Jones potential and Coulombic
potential respectively.202 In CoMSIA, similarity indices are calculated at regularly
placed grid points for the aligned molecules.203 CoMSIA includes additional
molecular descriptors like hydrophobic fields and hydrogen bond donor and
acceptor fields.205 Both 3D-QSAR methods give contour maps as output that can be
used to get some general insights into the topological features of the binding site.208
Kinase inhibitors, such as Imatinib, Erlotinib and Sunitinib, have recently been
approved for clinical use in the market as anti-cancer agents.210 The success of these
new drugs, has given a new impetus for developing better anti-cancer agents by
targeting kinases. Since PDK1 is a well validated anti-cancer target, ligand-based
drug design strategies could be used in lead optimization of PDK1 inhibitors. More
recently, a new series of indolinone derivatives were reported as PDK1
inhibitors.211,212 This new series of compounds were developed using an initial hit
identified from a high throughput screening (HTS) study.211, 212 Indolinones are well
known kinase inhibitor scaffold but a novel scaffold with respect to PDK1.
Developing predictive 3D-QSAR will be useful to predict the activity of new
compounds belonging to indolinone series as PDK1 inhibitors.
In this present work, the 3D-QSAR study on PDK1 inhibitors using CoMFA
and CoMSIA methods was carried out. We also carried out molecular docking of the
PDK1 inhibitors and further used the docked inhibitor structures to develop a
separate set of docking-based (or receptor-based) 3D-QSAR models. Such a study
allows us to compare the contour maps from two different strategies. Since the
X-ray crystal structure of PDK1 binding with inhibitors are available, this study
allows us to validate the potential and usefulness of the contour plots from
ligand-based methods. In this study, the 3D-QSAR models obtained from both the
ligand-based and receptor-based methods were all found to be statistically valid. The
models were capable of predicting the activity of the test-set molecules. The contour
plots obtained from the 3D-QSAR models correlate well with the detailed
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interactions between the ligands and active site residues in the docked
PDK1-inhibitor binding structures. The developed computational models are
expected to help the lead optimization and future rational drug design and discovery
efforts.

3.2. Computational Methods
3.2.1 Data sets and alignment
All compounds used in the present study were reported recently by Islam and
co-workers211,212 as inhibitors of PDK1. Of the 70 compounds reported, 56
compounds were used as a training set and the remaining 14 compounds were used
as a test set, based on a random selection. The compounds in the test set have a
range of biological activity values similar to that of the training set. The IC50 values
were converted into pIC50 (i.e. -logIC50) values. The pIC50 values are preferred due
to convention, as the negative logarithms give larger values to most active
compounds.213 The pIC50 values of the compounds studied cover an interval of
more than 3 log units. The structures of the compounds and their pIC50 values are
given in Table 3.1.
Identification of the bioactive conformation and molecular alignment of
compounds are two important steps in a 3D-QSAR study.214 The X-ray crystal
structures of this class of inhibitors bound with PDK1 are available from the protein
data bank (PDB).170 The bound conformation of compound 53 (PDB ID: 2PE2)212
had a relatively better resolution (2.13Å) and was used as a template for alignment
molecular structures. The 3D structures of all compounds were built using the
SYBYL software (Tripos, Inc.).171 The geometries of all compounds were optimized
by using semiempirical PM3 method. The optimized geometries were used to
perform single-point ab initio calculations at the HF/6-31G* level in order to
determine the electrostatic potential (ESP)-fitted atomic charges, i.e. the ESP
charges, that fit to the electrostatic potential at points selected according to the
Merz-Singh-Kollman scheme. 215 , 216 Two alignment methods were used. One
method, denoted by Alignment-I, is a substructure-based alignment. In this method,
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all compounds in the dataset were aligned to a common substructure (Figure 3.1)
using the ‘align database’ command in the SYBYL software. The other method,
denoted by Alignment–II, is the atom/centroid-based alignment. The selected atoms
and centroids of the molecules were used for alignment using the root-mean-squares
(RMS) fit method. The determined substructure and the reference atoms/centroids
used for the alignment were shown in Figure 3.1.

Table 3.1 Molecular structures of compounds used in the training and test sets and
their PDK1 inhibitory activity a
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Figure 3.1. The substructure and atoms/centroids used in alignments (A) The
substructure used for the ‘Common substructure-based alignment’ (Alignment-I); (B)
The atoms/centroids used in ‘Atom/Centroid based alignment’ is shown in asterisk
(Alignment-II).
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Figure 3.2 Superposition of all compounds in the training and test sets based on the
common substructure based alignment (Alignment-I).

3.2.2 3D-QSAR analysis
The CoMFA and CoMSIA models were generated by using the SYBYL
software with the default parameters. A regularly placed grid of 2.0 Å was created
around the aligned molecules. In CoMFA, the steric and electrostatic fields were
calculated at each intersection lattice point of the grid. A sp3 carbon atom with
charge +1.00 was used as a probe atom. The steric and electrostatic fields were
truncated at +30.00 kcal/mol.
In CoMSIA, the steric, electrostatic, hydrophobic, hydrogen bond donor and
acceptor descriptors were calculated at each lattice intersection of a regularly placed
grid of 2.0 Å. A probe atom with radius 1.0 Å, charge +1.0, and hydrophobicity of
+1.0 was used to calculate the respective fields. The attenuation factor α was set to
0.3. CoMSIA similarity indices (AF) for molecule j with atom i at grid point q are
calculated by Eq.(3-1):

A F,k ( j ) = −∑ ω probe,k ωik e
q

−αriq 2

(3-1)

where k represents the steric, electrostatic, hydrophobic, H-bond donor, or H-bond
acceptor descriptor. A Gaussian-type distance-dependence was used between the
grid point q and each atom i of the molecule.
The partial least-square (PLS)217 analysis was used to derive the 3D-QSAR
models. Sample-distance PLS (SAMPLS) algorithm

218

was used for the

leave-one-out (LOO) cross-validation. The optimum number of the components
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identified in the cross-validation was used in the final analysis. To further validate
the model, 100 runs of bootstrap analyses were performed. The models were also
rigorously analyzed by performing cross-validation using 5 groups and 2 groups in
the training set. Since only the number of groups and the number of validation times
can be controlled in the SYBYL ‘cross-validation’ process, the process was repeated
for 25 times. The models were also evaluated for their ability to predict the activity
of molecules in the test set. The predictive r2 (denoted by r2pred) for molecules in the
test set was calculated by using the Eq.(3-2):

r2pred = (SD – PRESS) /SD

(3-2)

where SD is the sum of the squared deviations of the individual biological activity
values for the test-set molecules from the mean activity value of the test-set
molecules, and PRESS is the sum of the squared deviations of the predicted activity
values from the actual activity values of the test-set molecules.

3.2.3. Molecular docking
Molecular docking was carried out to understand the detailed binding modes of
PDK1 binding with this series of inhibitors and develop receptor-based 3D-QSAR
models. X-ray crystal structures are available for PDK1 binding with three different
compounds in this series. The PDB IDs for X-ray crystal structures of PDK1 bound
with compounds 9, 35, and 53 are 2PE0, 2PE1, 2PE2, respectively.211,212 The X-ray
crystal structure (PDB ID: 2PE2) of PDK1 was used in molecular docking. Used in
the docking were the optimized geometries and the calculated ESP charges for all of
the compounds. Initial docking test runs were carried out on compounds 9, 35, and
53 using four different docking approaches and the ability to reproduce the X-ray
crystal structures were analyzed. Of the four docking approaches used in this study,
three are associated with the use of the popularly used docking programs, i.e.
DOCK,178 AutoDock,219 and FlexX.172 The fourth is an approach combining FRED
docking 220 , 221 with energy minimization calculations on the docked binding
structures, denoted by FRED-EM for convenience. Based on our initial docking test
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runs, we finally selected FlexX and FRED-EM for molecular docking with all 70
ligands. It should be noted that the different docking programs have different default
choices/parameters and the above results are limited to this series of molecules and
should not be taken as the mutual comparison of software performance in general.
DOCK. The DOCK 6.1 program uses the anchor and grow strategy for flexible
ligand docking.178 The protein was considered to be rigid and the ligand molecules
were flexible. The ligand orientations were scored through the use of a force
field-based energy scoring function and the top-scored binding structure was
selected. The active site spheres were prepared using SPHGEN program.183 The
spheres were selected such that they cover the entire ligand-binding region. These
spheres served to orient ligands in the active site.183 A box was created to enclose the
spheres and the energetic grid was created by the GRID module of DOCK program.
Grid calculations were carried out by using 0.3 Å grid spacing. Both the anchor and
the ligand were minimized. 500 minimization iterations and a clash overlap value of
0.5 were used for the docking runs.
AutoDock. The AutoDock 4.0 program performs automated and flexible ligand
docking.219 The AutoDock Tools (ADT) was used in the preparation of protein and
ligands. The molecular docking was performed using the Lamarkian genetic
algorithm (LGA). The size of the grid, in which both the enzyme and the ligand
were embedded, was set to be 60 Å × 60 Å × 60 Å along the x, y, and z directions of
Cartesian coordinate system. This size of grid is large enough to cover all the protein
atoms near the docking site. The default parameters in the AutoDock were used in
this study. For docking with each ligand, the top-10 docked poses were compared to
the corresponding X-ray crystal structure.
FlexX. We also analyzed docking using FlexX module of SYBYL.172 In FlexX
method, the protein is kept rigid and the ligand flexibility is explored. In this
program, the ligand molecule is split up into fragments and is built up by performing
conformational search of the ligand in the active site.173 Only the best conformation
was built upon and the others are discarded. The active site was defined as residues
within 6.5Å around the bound ligand. Based on the crystal structure the region with
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residues Leu88, Val96, Leu212, Ser160, and Ala162 were defined as the core
sub-pocket. The ligands were docked using the multiple-ligand docking option of
the FlexX. The top-30 docked orientations were generated for each ligand and the
best docked structure was selected.
FRED docking followed by energy minimization (FRED-EM). We first
generated and energy-minimized various molecular orientations and conformations
of each ligand by using Omega (Open Eye Scientific Software) and Amber9
programs, 222 producing ~600 different minimum-energy conformations. Omega
sampling is capable of selecting a ligand conformation similar to that of the targeted
X-ray crystal structure by using an appropriate option (the default) including a
low-energy cutoff to discard high-energy conformations, a low RMSD value below
which two conformations are considered to be similar, and a maximum of 500 to
1000 output conformations.223 We checked to make sure that the sampling was
sufficient

enough

to

include

at

least

one

conformer

of

the

scaffold

(3-[(Pyrrol-2-yl)-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one) similar to the one
found in the X-ray complex. FRED (OpenEye Scientific Software) docking
calculations were carried out using protein structures with all hydrogen atoms and
with the binding site definitions provided by FRED Receptor program (Open Eye
Scientific Software).
FRED docking roughly consisted of two steps, i.e. shape fitting and
optimization. During the shape fitting, the ligand was placed into a 0.5 Å-resolution
grid box encompassing all active-site atoms (including hydrogen atoms) using a
smooth Gaussian potential.220 A series of two optimization filters were then
processed, consisting of rigid-body optimization and optimization of the ligand pose
in the dihedral angle space. In the optimization step, four scoring functions are
available: Gaussian shape scoring,220 ChemScore,224 PLP,225 and ScreenScore.226
Preliminary docking trials led us to select ChemScore for the optimization filters. In
separate docking runs, the conformational poses of each ligand that passed the
shape-fitting and optimization filters were submitted to the energy minimization
using AMBER9 program. During the energy minimization in vacuum, the
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non-bonded cutoff and the dielectric constant were set to group-based (20 Å cutoff
distance) and distance-dependent (ε=4r), respectively.227 The pose with the lowest
interaction energy was selected as the best binding mode.

3.3. Combined receptor-based and ligand-based 3D-QSAR models and their
evaluation
3.3.1. 3D-QSAR models
The results obtained from the CoMFA and CoMSIA models using a training
set of 56 compounds are summarized in Table 3.2. The structural alignment of the
compounds is one of the important steps in the development of a 3D-QSAR
model.202

Hence

we

tested

two

different

alignment

rules

namely

the

substructure-based alignment (Alignment-I) and atom/centroid-based alignment
(Alignment-II). For all of the 3D-QSAR models, the leave-one-out (LOO)
cross-validation was performed first to identify the cross-validated correlation
coefficient (q2) values. Then the number of components identified in the LOO
cross-validation process was used in the final non-cross-validated PLS run. The
developed 3D-QSAR models were analyzed in terms of a number of statistical
parameters, namely the q2, non-cross-validated correlation coefficient (r2), standard
error estimate (SEE), and F-statistic values. All models developed have a good q2
value of >0.6. A q2 value of greater than 0.5 is usually considered significant.228 In
CoMFA analyses, the substructure-based alignment (Alignment-I) led to the models
with larger q2 and r2 values than those obtained from Alignment-II. In the case of
CoMSIA, different combinations of the descriptors were also studied. The CoMSIA
model with steric, electrostatic, hydrophobic, donor, and acceptor descriptors was
associated with larger q2 and r2 values. It has been reported that, in addition to the q2
value, r2pred should also be used to choose the predictive QSAR models.229 Hence
the CoMSIA model (denoted by CoMSIA-1d) from alignment I was selected for
final analysis based on the larger r2pred value and used to predict the activity of the
compounds (see Table 3.2).
The CoMFA-1a model (see Table 3.2) has a q2 value of 0.737 and an r2 value
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of 0.907. The model was developed with 5 components. It has an F value of 97.053
and an SEE value of 0.354. The CoMSIA-1d model has a q2 value of 0.824 and an r2
value of 0.991. It was developed with 9 components and has an F value of 589.262
and an SEE value of 0.112. The high r2, q2, and F values along with the low SEE
values suggest that the models are reasonable and should have a good predictive
ability. The results also reveal that the electrostatic and hydrophobic and hydrogen
bond donor features play an important role in determining the biological activity of
these inhibitors. In CoMSIA, the steric feature is found to have the least contribution
to the activity. Based on the CoMFA-1a model, the contributions from the steric and
electrostatic fields were found to be around ~46% and ~54%, respectively.
According to the CoMSIA-1d model, the steric field has ~8% contribution, the
electrostatic field has ~23% contribution, hydrophobic field has ~23% contribution,
donor feature has 24%, and acceptor feature has ~22% contribution.
The 3D-QSAR models were further validated using an external test set of 14
compounds. CoMFA-1a and CoMSIA-1d models all gave good predictions of both
the training- and test-set compounds (see Supporting Information). Both the
CoMFA-1a and CoMSIA-1d models have the larger r2pred values, i.e. 0.812 and
0.883, respectively. The predicted activity of the compounds and their residuals
(deviations) are given in Table 3.5, and the plots obtained were depicted in Figure
3.2. In both models (CoMFA-1a and CoMSIA-1d) the deviations of the predicted
pIC50 values from the corresponding experimental pIC50 values are always smaller
than 1 log unit.
We also performed additional cross-validation analyses using more groups in
the training set. The CoMFA-1a and CoMSIA-1d models were further analyzed by
additional rigorous statistical cross-validation using five and two groups in the
training set. Each cross-validation process was repeated for 25 times and the results
are tabulated in Table 3.3. In the case of cross-validation using two groups, the
training set is divided into two groups and 50% of the compounds are dropped out in
the training process and the activities of those compounds are predicted. In the case
of cross-validation using 5 groups, 20% of the compounds are left out in the training
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process and the activity values of those compounds are predicted. As shown in Table
3.3, the average q2 values obtained in this way was only slightly lower than the q2
values obtained with the LOO method. These results suggest that the high q2 values
were not obtained by chance correlation and the obtained CoMFA-1a and
CoMSIA-1d models are stable and valid. To further obtain statistical confidence
limits, 100-runs bootstrap analyses were also carried out. The bootstrapping results
are considered as good indicators concerning whether there exist possible chance
correlations.230 Our analyses gave a bootstrap r2 value of 0.942 and 0.994 for
CoMFA-1a and CoMSIA-1d, respectively. The high values of bootstrap r2 further
confirm the robustness of our CoMFA-1a and CoMSIA-1d models.

Table 3.2 Summary of the results obtained from the CoMFA and CoMSIA
analysesa,201
Alignment-I
PLS statistic CoMF CoMSI CoMSI
A
A
A 1c
1a
1b
SE
SE
SEH
2
q
0.737 0.712 0.772
SEP
0.595 0.623 0.548
2
r
0.907 0.900 0.921
SEE
0.354 0.366 0.323
F value
97.053 90.362 148.011
NOC
5
5
4
2
r pred
0.812 0.834 0.911
2 b
r bs
0.942 n/a
n/a
Fraction
Steric
0.456 0.266 0.122
Electrostatic 0.544 0.734 0.476
Hydrophobi n/a
n/a
0.402
c
Donor
n/a
n/a
n/a
Acceptor
n/a
n/a
n/a
a

Alignment-II
CoMSI CoMF CoMSI CoMSI
A 1d
A
A
A
1e
1f
1g
SEHDA SE
SE
SEH
0.824
0.716 0.732 0.782
0.507
0.619 0.611
0.536
0.991
0.882 0.897 0.919
0.112
0.398 0.372 0.327
589.262 74.774 86.976 144.231
9
5
5
4
0.883
0.743 0.819 0.909
0.994
n/a
n/a
n/a

CoMSI
A
1h
SEHDA
0.837
0.493
0.993
0.099
685.762
10
0.877
n/a

0.088
0.230
0.230

0.459
0.541
n/a

0.281
0.719
n/a

0.128
0.460
0.412

0.093
0.227
0.233

0.235
0.217

n/a
n/a

n/a
n/a

n/a
n/a

0.223
0.224

CoMFA and CoMSIA analyses were preformed using the training set of 56

compounds; Alignment-I refers to substructure-based alignment; Alignment-II refers
to atom/centroid-based alignment; S=steric, E=electrostatic, H=hydrophobic,
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D=donor and A=acceptor. b100 runs of bootstrap analysis.
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Figure 3.3 Plots of the predicted pIC50 values versus the actual pIC50 values using
the training set of 56 compounds and the test set of 14 compounds.201 (A)
CoMFA-1a model using substructure-based alignment; (B) CoMSIA-1d model using
substructure-based alignment; (C) CoMFA-2a model using the docking-based
alignment; (D) CoMSIA-2b model using docking-based alignment.
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Table 3.3 Result of the cross-validation analyses using five and two groups201
q2 a
Using five groups
Using two groups
CoMFA-1a CoMSIA-1d
CoMFA-1a CoMSIA-1d
mean
0.725
0.794
0.67
0.730
high
0.779
0.863
0.781
0.821
low
0.631
0.699
0.562
0.637
a
2
Cross-validated q values obtained from using five and two groups with the
optimum number of components on average of 25 runs.
3.3.2 3D-QSAR contour maps
One of the attractive features of the CoMFA and CoMSIA modeling is the
visualization of the results as 3D-coefficient contour plots. The contour maps were
generated as scalar products of coefficients and standard deviation, associated with
each CoMFA or CoMSIA column. The maps generated depict regions having scaled
coefficients greater than 80% (favored) or less than 20% (disfavored). In the case of
CoMFA, the green contour shows favorable steric interaction and the yellow
contours show the region where steric group is not favored. The red contour shows
favorable electronegative region and the blue contour shows the region where
electropositive region is favored. These contour maps (as depicted in Figures 3.4 and
3.5) give us some general insight into the nature of the receptor-ligand binding
regions.
CoMFA contour maps One of the most active compounds in the series
(compound 60) is shown superimposed with the CoMFA contour maps in Figure 3.4.
The yellow contour region near #7 position of indolinone ring shows that,
substituents at this position have unfavorable steric interactions. This is consistent
with the reported experimental results. Compounds 4 and 8 have a methyl and
hydroxyl group, respectively, at the #7 position and both compounds have a lower
activity. The yellow contours are present below the plane of the indolinone group.
This shows that there will be an unfavorable steric interaction if bulky substitutions
were introduced in that region. This is in agreement with the reported X-ray crystal
structure of PDK1 bound with compound 53 (PDB ID: 2PE2).212 The indolinone
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group is sandwiched between hydrophobic residues. If bulky groups are introduced
below the plane of indolinone group, they will have an unfavorable steric interaction
with Leu212.

Figure 3.4 CoMFA steric and electrostatic contour maps around compound 60;
Green isopleths enclose areas where steric interaction is favored. Yellow contours
are areas where the steric interaction is disfavored. Blue region represents the area
where electropositive group is favorable for the binding. Red region refers to the
area where an electronegative group is favorable for the binding.
The green region near the urea group shows a favorable steric interaction in this
position. The red contour near the carbonyl of urea group shows that electronegative
groups are favored in this region. This explains the lower activity of compound 23.
Compound 23 has (-CH2NH2) substituent at #5 position of indolinone group and has
an IC50 value of 1000 nM. Similarly, red contour region (favorable electronegative
group) is found in 4′ substituents at the pyrrole group. Compounds 39 to 48 have
carbonyl group at this position and have an IC50 value in low nanomolar range. Blue
contour region shows that electropositive groups are favored in this region. The
–NH2 of urea group is present near this region and explains the increased activity of
compound 26 (IC50 = 18 nM) compared to compound 25 (IC50 = 55 nM).
CoMSIA contour maps In the case of CoMSIA, we get additional insight from
the hydrophobic, acceptor, and donor features. The CoMSIA steric and electrostatic
contour maps were similar to the ones obtained from the CoMFA model. Figure 3.5a
shows compound 60 superimposed on the CoMSIA steric, electrostatic, and
hydrophobic contour plot.
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(A)

(B)

Figure 3.5. CoMSIA contour maps around compound 60. (A) CoMSIA steric,
electrostatic, and hydrophobic contour maps around compound 60. Green and
Yellow contours represent regions with favorable and unfavorable steric interactions.
Blue and red contours represent regions which favor electropositive and
electronegative

groups

respectively.

Cyan

isopleths

enclose areas

where

hydrophobic groups could enhance the activity. White contours represent area where
hydrophobic groups are disfavored. (B) CoMSIA acceptor and donor contour maps
around compound 60. Orange isopleths indicate regions where acceptor group is
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favored and red contour indicates region where acceptor groups are not favored.
Magenta and purple contours represent favorable and unfavorable hydrogen bond
donor regions, respectively.
The yellow contour near #7 position of indolinone ring shows an unfavorable
steric interaction at this region. This is also observed in the CoMFA model and
explains the lower activity of compounds 4 and 7. In addition, the CoMSIA model
shows that #5’ position of pyrrole ring has an unfavorable steric interaction. This
agrees with the reported experimental results. Compounds 12 to 14 and 42 have a
methyl or ethyl substituent at this position and have a lower activity. Green contour
is present between #4 position of indolinone group and the methylidenyl (>C=CH-)
group at the #3 position. This shows that, steric interaction is favored at this region.
This agrees with the reported experimental results. Compounds 27 to 29 have bulky
substituents in this region and have a higher activity. Similarly, when we compare
compound 2 (IC50 = 510 nM) with 5 (IC50 = 1000 nM), we find that 4-methyl group
(compound 2) is slightly favored than 4-OH group (compound 5) in this region,
which is consistent with the relative IC50 values. The red contour near the carbonyl
of urea group at #5 position of indolinone ring shows that electronegative groups are
favored in this region. The blue contours occur immediately adjacent to it. It shows
the favorable electropositive region. Another favorable electronegative region is
present near the pyrrole ring. The favorable hydrophobic region (cyan contour) is
present near the methylidenyl (>C=CH-) group at #3 position of indolinone ring
(Figure 3.5a). This is consistent with the increased activity observed for compounds
27 to 29. In Figure 3.5a, white contour showing an unfavorable hydrophobic
interaction region is present near #5 position of indolinone group. This explains the
lower activity of compound 3 (IC50 = 2700 nM) compared to compound 6 (IC50 =
340 nM). The hydrogen bond donor and acceptor contour superimposed on
compound 60 is shown in Figure 3.5b. The orange contour shows a favorable
hydrogen bond acceptor region and the red contour shows regions in which
hydrogen bond acceptor is not favored. The magenta color shows the favorable
hydrogen bond donor contour and the purple color shows regions in which a
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hydrogen bond donor group is not favored. From the contour plot we can see that the
carbonyl oxygen of urea is present in the favorable hydrogen bond acceptor group
region. This also agrees with the favorable electronegative contour observed in
Figure 3.5a. The favorable hydrogen bond donor contour is present near the –NH2 of
urea group. This is in agreement with the reported X-ray crystal structure of PDK1
bound with compound 53 (PDB ID: 2PE2).212 In the crystal structure, the
carboxylate side chain of Glu130 is present near –NH2 of urea group and could have
a favorable interaction. There are unfavorable hydrogen bond donor and acceptor
contours (Figure 3.5b, red contour and magenta contour) above the plane of the
methylidenyl (>C=CH-) group (at #3 position of indolinone ring). Taking into
account the hydrophobic contour from Figure 3.5a, we find that, this region has only
a favorable hydrophobic interaction. Donor and acceptor groups are not preferred in
this region. This explains the lower activity of compounds 31 to 34, as they have
either donor or acceptor group in this region. There is an additional unfavorable
hydrogen bond donor contour (purple) near the >NH of indolinone group. The X-ray
crystal structure (PDB ID: 2PE2) shows that, the -NH- of indolinone group has a
hydrogen bonding interaction with the backbone carbonyl oxygen of Ser160. The
unfavorable hydrogen bond donor contour is present in the place where carbonyl
group of serine backbone is present. So this purple contour represents that the -NHof indolinone ring is the optimal or ideal group at this position. If a hydrogen bond
donor substitution is made at #1 position of indolinone ring (instead of -NH- on the
ring), there will be clash with the backbone atom and such a hydrogen bond donor
will not be favorable for the activity.

3.3.3 Binding structures and docking-based 3D-QSAR models
In addition to the ligand-based 3D-QSAR, we have also performed molecular
docking for all of the 70 inhibitors to understand the nature of interactions of these
compounds with PDK1. We also carried out molecular docking and receptor-based
3D-QSAR modeling, i.e. using the docked poses of the 70 compounds in the PDK1
active site. The contour plots from the receptor-based 3D-QSAR models directly
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relate the favorable and unfavorable contours to the corresponding detailed
protein-ligand interactions in the active site. X-ray crystal structures are available for
PDK1 binding with three different compounds (9, 35, and 53) in this series. The
PDB IDs for X-ray crystal structures of PDK1 binding with compounds 9, 35, and
53 are 2PE0, 2PE1, and 2PE2, respectively.211,212 As the first step, the docking
reliability was tested using the PDK1 structure in 2PE2 for docking with compounds
9, 35, and 53. For molecular docking with all ligands, we used the optimized
geometries and calculated ESP charges. Three commonly used docking programs
(DOCK, AutoDock, and FlexX) and the aforementioned FRED-EM approach were
used for these three inhibitors. We found that only FlexX and FRED-EM were able
to reproduce the X-ray crystal structures for all of the three ligands. The AutoDock
was unable to reproduce the pose of compound 35 in PDK1. All of the 10 AutoDock
poses for compound 35 were significantly different from that observed in the X-ray
crystal structure. In the case of DOCK, compound 53 failed to dock into the active
site.
In light of the above docking tests, the FlexX and FRED-EM were finally
selected for carrying out molecular docking for all of the 70 inhibitors. In the case of
FlexX-based docking, 69 compounds were docked in a similar pose. One exception
is compound 37, in which the -NH- of pyrrole ring is flipped by ~180o compared to
the X-ray crystal structure. So, compound 37 was omitted from the training set of
the 3D-QSAR modeling using the molecular structures obtained from the FlexX
docking. The FRED-EM approach was able to dock all of the 70 compounds into the
active site with a similar pose. The docked poses of all 70 compounds using this
method were shown in Figure 3.6. The docked poses serve as a very good starting
point for carrying out 3D-QSAR modeling. As discussed earlier, the alignment of
compound structures plays a key role in developing successful 3D-QSAR models.
Hence the docked poses of the ligands were used to develop receptor-based
3D-QSAR models.
In the development of 3D-QSAR models based on FlexX docking and
FRED-EM docking, we found that the models developed with FRED-EM docking
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(CoMFA-2a and CoMFA-2b) had larger q2, r2, and r2

pred

values. Hence CoMFA-2a

and CoMSIA-2b were used in our further analysis below. The results are
summarized in Table 3.4.

(A)

(B)

Figure 3.6 Docked poses of all 70 inhibitors in the active site of PDK1. (A) The
trace view of PDK1 backbone is shown in magenta color. (B) Different view of the
70 docked molecules; PDK1 is shown in Connolly surface and the surface is colored
according to cavity depth.
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Table 3.4 Summary of the results obtained from the docking-based CoMFA and
CoMSIA analyses201
PLS statistic
q2
SEP
r2
SEE
F value
NOC
r2pred
r2bs c
Fraction
Steric
Electrostatic
Hydrophobic
Donor
Acceptor
a

FRED-EMa
COMFA-2a COMSIA-2b
SE
SEHDA
0.729
0.79
0.598
0.521
0.884
0.909
0.392
0.343
96.878
173.423
4
3
0.736
0.840
0.911
0.926

FlexXb
CoMFA-3a
CoMSIA-3b
SE
SEHDA
0.662
0.738
0.663
0.615
0.854
0.992
0.437
0.109
99.093
698.659
3
8
0.726
0.806
n/a
n/a

0.428
0.572
n/a
n/a
n/a

0.459
0.541
n/a
n/a
n/a

0.079
0.283
0.245
0.237
0.156

0.086
0.248
0.229
0.271
0.167

CoMFA and CoMSIA analyses were preformed using the training set of 56

compounds and the alignment is based on the docked poses from FRED-EM method.
b

CoMFA and CoMSIA analyses were preformed using the training set of 55

compounds and the alignment is based on the FlexX docked poses; S=steric,
E=electrostatic, H=hydrophobic, D=donor and A=acceptor. c 100 runs of bootstrap
analysis.

CoMFA. The CoMFA-2a model developed with the docked poses has a q2
value of 0.729 and r2 value of 0.884. The validity of the model was tested with the
external test set of 14 compounds. CoMFA-2a model gives satisfactory activity
(pIC50) predictions for both the training and test sets. It is also interesting to note that
the contour plots obtained from the docking-based model correlate well with the
detailed interactions between the compounds and the active site residues (Figure
3.7b). The predicted activity of the compounds and their residuals are provided in
Table 3.6 and the plots obtained are depicted in Figure 3.3c. The deviations of the
predicted pIC50 values are greater than 1 log unit only for two compounds (28 and
33). The residuals between actual and predicted values for compounds 28 and 33 are
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-1.25 and -1.12, respectively. A yellow contour present near #7 position of the
indolinone ring represents an unfavorable steric interaction in this region. This is
consistent with the corresponding protein-ligand binding structure obtained from
molecular docking. A comparison between the docked structure and the contour
plots reveals that the yellow contour is present in the region of Leu159 and Val143.
Hence, bulky substitutions at #7 position of indolinone ring will have an unfavorable
steric interaction. This also explains the lower activity of compounds 4 and 8.
Another unfavorable steric interaction region (yellow contour) is present near the
pyrrole and phenyl ring. Our docked model shows that a bulky substituent at this
position will have an unfavorable steric interaction with the backbone of Lys163 and
side chain of Tyr161. The red contour represents a favorable electronegative region
and is present near the carbonyl of urea group. According to the docked structure,
this favorable electronegative region is surrounded by Lys111, Thr222, and
backbone -NH- group of Asp223. This explains the increased activity expected from
the introduction of electronegative groups in this region. The red contour around the
phenyl ring shows a favorable electronegative region. This contour is present near
the backbone -NH- of Gly165 residue. Thus it is expected to have a favorable
interaction with electronegative groups like carbonyl. The amino group on 3″
position of phenyl ring is present near the backbone carbonyl group of Asn164. This
explains the increased activity of compounds with electropositive groups in this
region. Blue contour is present in the region around urea group. Glu130 and Ser94
are present in this region. This reveals that the activity of the compound can be
increased further by extending the substituents and introducing suitable
electropositive groups to interact with these residues.
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(A)

(B)

Figure 3.7 CoMFA contour maps around compound 60 (A) CoMFA steric and
electrostatic contour maps around compound 60; Green isopleths enclose areas
where a steric bulk could enhance the activity. Yellow contours are areas where the
steric interaction is disfavored. Blue region represents the area where a positive
charge is favorable for the binding. Red region refers to the area where a negative
charge is favorable for the binding. (B) The CoMFA contour plots were shown
superimposed with PDK1 active site residues. Compound 60 is shown in magenta
color. Hydrogen atoms and some side-chains were not shown for better clarity of
this figure.
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(A)

(B)

Figure 3.8 CoMSIA contour maps around compound 60 (A) CoMSIA steric,
electrostatic, and hydrophobic contour maps around compound 60. Green isopleths
indicates region where there is favorable steric interaction. Yellow contours are areas
where the steric interaction is disfavored. Blue region represents the area where a
positive charge is favorable for the binding. Red region refers to the area where a
negative charge is favorable for the binding. Cyan isopleths enclose areas where
hydrophobic groups could enhance the activity. White region represents area where
hydrophobic groups are disfavored. (B) CoMSIA acceptor and donor contour maps
around compound 60. Orange isopleths indicate regions where acceptor group is
favored and red regions indicate where acceptor groups are not favored. Magenta
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region indicates areas where hydrogen bond donor groups are favored. The purple
region indicated areas where hydrogen bond donors are disfavored.
CoMSIA. The CoMSIA model developed with the docked poses has a q2 value
of 0.79 and r2 value of 0.909. The validity of the model was tested with the external
test set of 14 compounds. CoMFA-2b model gives satisfactory activity (pIC50)
predictions for both the training and test sets. The predicted activity of the
compounds and their residuals are provided in Table 3.6 and the plots obtained were
depicted in Figure 3.3d. The deviation of the predicted pIC50 value from the
corresponding experimental value was greater than 1 log unit only for compound 30.
The residual (deviations) between actual and predicted values for compound 30 is
1.09. In Figure 3.8a, the green contour along with white contour around the urea
group shows that hydrophobic substituents are not favored at this region but the urea
group has a favorable steric fit into the pocket surrounding this group. This is in
agreement with the crystal structure as this group is surrounded by Thr222, Lys111,
and Asp 223. Compound 26 with urea derivative has a higher activity (IC50 = 18 nM)
than compounds 16 (IC50 = 290 nM) and 18 (IC50 = 260 nM) with 5-sulfonamide
and 5-carboxylate groups, respectively. The cyan contour shows a favorable
hydrophobic interaction with substituents in the methylidenyl (>C=CH-) group (at
#3 position of indolinone ring). This is in agreement with the experimental
observation that compounds 36 to 38 with a hydrophobic susbtituent in this region
have an increased activity. The blue contour shows a favorable electropositive
region near the amino group on the phenyl ring. The amino group of this molecule is
present near the backbone carbonyl group of Asn164. This explains the increased
activity of compounds with electropositive groups in this region. The orange contour
shows a favorable acceptor region which corresponds to the interaction with Lys111.
The red contour in Figure 3.7b corresponds to the unfavorable acceptor groups.
Hydrophobic residues like Val96 and Leu88 are present in this region. This explains
the unfavorable hydrogen bond donor (purple) and acceptor (red) contour in this
region. The unfavorable hydrogen bond donor contour near the 2-carbonyl group of
indolinone ring corresponds to the -NH- backbone of Ala162. This shows that
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H-bond donor is not favored in this region.

3.4. Significance and limitation of the combined 3D-QSAR modeling and
molecular docking study
Indolinone is one of the ten most frequently encountered sub-structures in
kinase inhibitors.231 Reasonable 3D-QSAR models will be of great help in further
rational design of new ligands of indolinone series as PDK1 inhibitors. Through a
combined use of 3D-QSAR modeling and molecular docking, we have developed
ligand-based and docking-based 3D-QSAR models for the PDK1 inhibitors. The
high r2 and q2 values of the 3D-QSAR models suggest that PDK-1 binds with all of
the examined inhibitors in a similar binding mode. Combining molecular docking
with 3D-QSAR modeling offers a more interesting, integrated approach and allows
us to utilize structural information of the protein for 3D-QSAR modeling. The
advantage of docking-based model is that we can directly superimpose the contour
plots into the protein active site. Such superimposition will also allow us to check
the correlation between the contour plots and the corresponding receptor residues
present near them. Since the docked pose gives the bioactive conformation of the
ligands, this method helps to overcome the error which may arise by using an
incorrect conformation of the ligand. The results obtained from molecular docking
and those from 3D-QSAR modeling can complement and validate each other. All of
the structural insights obtained from molecular docking and 3D-QSAR contour
maps are consistent with the available experimental activity data, suggesting that the
microscopic enzyme-inhibitor binding structures obtained from the molecular
docking are reasonable and that the developed 3D-QSAR models are reliable.
Another interesting aspect is the nature of contour plots from two different
approaches namely ligand-based and receptor-based QSAR modeling. In the former,
no receptor information is used, whereas in the latter docked poses were used as the
starting alignment to carry out QSAR analysis. The contour plots from both
approaches are very similar. As discussed above, the contour maps obtained from
both models were consistent with the active site. These results show one of the
84

potential applications of ligand-based study in drug design. For many important
therapeutic targets, the experimentally solved X-ray structure is not available. But
there are known ligands against such targets which were developed through
traditional medicinal chemistry approach. In such cases, ligand-based approaches
like 3D-QSAR can be used to get an insight into the nature of the active site. We
have previously shown one such application in understanding the nature of active
site of microsomal prostaglandin E synthase-1 and its interaction with the
inhibitors.206 In our present study, we have also found that the contour plots from
ligand-based alignment which does not include any receptor information are
consistent with the receptor active site.
One possible disadvantage of the docking-based 3D-QSAR method is that the
small variation in docking pose could give rise to “noise” in the 3D-QSAR model. It
is reported that the slight variation in the docked poses could create variations in the
ligand field and will weaken the ability of the partial least-squares (PLS) to detect
the real “signal”.232 The general limitation of 3D-QSAR modeling is that it cannot
be used if the ligands have different microscopic binding modes with the enzyme. In
such cases, the combined molecular docking and 3D-QSAR modeling approach
cannot be used. Whenever 3D-QSAR modeling can be used for a series of
compounds, developing both ligand-based and docking-based 3D-QSAR models
could help us to overcome some possible error which may occur if we use one
particular method.
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Table 3.5 The actual and predicted inhibitory activity values (pIC50) and the
residuals of the training- and test-set molecules.201
Compound
1
2
4
5
7
8
9
11
12
13
14
15
16
17
18
19
20
23
24
26
27
29
30
31
32
33
34
35
36
37
39
40
41
42
43
44
45
47

Actual
pIC50
5.74
6.29
4.58
6.00
6.05
4.58
7.10
6.55
6.17
5.64
5.96
6.24
6.54
6.17
6.59
6.92
6.70
6.00
6.28
7.74
7.17
7.54
7.47
5.38
5.41
5.21
5.27
8.30
8.52
8.05
8.05
8.05
7.41
7.24
7.57
7.96
7.54
7.85

CoMFA-1a
Predicted
Residual
pIC50
5.69
0.05
6.04
0.26
5.33
-0.75
5.93
0.07
5.93
0.12
5.32
-0.74
6.56
0.54
6.29
0.26
5.94
0.23
5.91
-0.27
6.09
-0.13
6.22
0.02
6.24
0.30
6.65
-0.48
6.36
0.23
6.26
0.66
6.65
0.06
6.37
-0.37
6.77
-0.49
7.86
-0.12
6.52
0.65
7.02
0.52
6.91
0.56
5.47
-0.09
6.29
-0.88
5.21
0.00
5.20
0.07
8.09
0.21
8.22
0.30
8.82
-0.77
8.04
0.01
8.29
-0.24
7.31
0.10
7.16
0.08
7.52
0.05
7.60
0.36
7.44
0.10
7.75
0.10
86

CoMSIA-1d
Predicted
Residual
pIC50
5.58
0.16
6.12
0.17
5.00
-0.42
6.04
-0.04
6.03
0.02
4.45
0.13
7.00
0.10
6.41
0.14
5.99
0.18
5.76
-0.12
6.09
-0.13
6.23
0.01
6.52
0.02
6.21
-0.04
6.57
0.02
6.91
0.01
6.74
-0.04
6.08
-0.08
6.30
-0.02
7.74
0.00
7.18
-0.01
7.57
-0.03
7.49
-0.02
5.33
0.05
5.34
0.07
5.13
0.08
5.43
-0.16
8.31
-0.01
8.74
-0.22
7.84
0.21
7.96
0.09
8.01
0.04
7.57
-0.16
7.16
0.08
7.70
-0.13
7.89
0.07
7.57
-0.03
7.84
0.01

Table 3.5 (Continued)
Compound
Actual
pIC50
7.77
48
7.68
49
8.10
50
7.35
51
8.40
52
8.40
53
7.72
55
7.43
57
8.30
58
8.52
60
8.00
61
8.30
63
8.00
64
8.22
65
8.40
66
8.30
68
8.00
69
8.52
70
Test set
5.57
3
6.47
6
6.55
10
6.24
21
6.00
22
7.26
25
7.85
28
8.00
38
7.51
46
8.22
54
7.29
56
8.10
59
8.10
62
8.30
67

Predicted
pIC50
7.78
7.93
8.03
7.18
8.21
8.21
7.99
7.61
8.02
8.28
8.18
8.50
8.06
8.28
8.36
8.43
8.35
8.58

Residual

Residual

-0.01
-0.25
0.07
0.17
0.19
0.19
-0.27
-0.18
0.28
0.24
-0.18
-0.20
-0.06
-0.06
0.04
-0.13
-0.35
-0.06

Predicted
pIC50
7.68
7.71
8.12
7.38
8.34
8.36
7.76
7.49
8.30
8.52
8.02
8.27
8.06
8.22
8.38
8.30
7.96
8.54

6.12
6.09
6.24
5.86
5.83
7.12
6.94
8.48
7.71
7.91
7.45
8.01
8.39
8.41

-0.55
0.38
0.31
0.38
0.17
0.14
0.91
-0.48
-0.20
0.31
-0.16
0.09
-0.29
-0.10

5.83
6.38
6.47
6.63
5.75
6.48
7.65
8.22
7.84
7.88
7.53
8.05
8.16
8.29

-0.26
0.09
0.08
-0.39
0.25
0.78
0.20
-0.22
-0.33
0.34
-0.24
0.05
-0.06
0.01

0.09
-0.03
-0.02
-0.03
0.06
0.04
-0.04
-0.06
0.00
0.00
-0.02
0.03
-0.06
0.00
0.02
0.01
0.04
-0.02

Table 3.6 The actual and predicted inhibitory activity values (pIC50) and the
residuals of the training- and test-set molecules using docking based 3D-QSAR.201
Compound
1

Actual
pIC50
5.74

CoMFA-2a
Predicted
Residual
pIC50
5.71
0.03
87

CoMSIA-2b
Predicted
Residual
pIC50
5.69
0.05

Table 3.6 (Continued)
Compound
Actual
pIC50
6.29
2
4.58
4
6.00
5
6.05
7
4.58
8
7.10
9
6.55
11
6.17
12
5.64
13
5.96
14
6.24
15
6.54
16
6.17
17
6.59
18
6.92
19
6.70
20
6.00
23
6.28
24
7.74
26
7.17
27
7.54
29
7.47
30
5.38
31
5.41
32
5.21
33
5.27
34
8.30
35
8.52
36
8.05
37
8.05
39
8.05
40
7.41
41
7.24
42
7.57
43
7.96
44
7.54
45
7.85
47
7.77
48
7.68
49
8.10
50
7.35
51

Predicted
pIC50
5.86
5.38
5.83
5.96
5.39
6.52
6.14
6.03
5.83
5.84
6.27
5.95
6.46
6.38
6.26
6.64
6.73
6.64
7.86
6.82
7.20
6.56
5.48
5.93
6.33
5.16
7.89
8.20
8.51
8.24
8.14
7.42
7.30
7.56
7.54
7.37
7.63
7.71
7.73
7.81
7.66

Residual
0.43
-0.80
0.17
0.09
-0.81
0.59
0.41
0.14
-0.19
0.12
-0.03
0.60
-0.29
0.21
0.66
0.06
-0.73
-0.36
-0.12
0.35
0.34
0.91
-0.10
-0.52
-1.12
0.11
0.41
0.32
-0.46
-0.19
-0.09
-0.01
-0.05
0.01
0.42
0.18
0.22
0.06
-0.05
0.29
-0.31
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Predicted
pIC50
5.85
5.47
5.64
5.86
5.36
6.50
6.00
6.06
5.95
6.00
6.04
6.57
6.13
6.85
6.74
6.65
5.74
6.43
7.78
7.18
7.72
6.38
5.79
5.45
5.90
5.57
7.92
8.19
8.54
7.89
7.76
7.34
7.35
7.72
7.80
7.66
7.68
7.58
7.56
7.87
7.33

Residual
0.44
-0.89
0.36
0.19
-0.78
0.60
0.55
0.11
-0.31
-0.04
0.20
-0.03
0.04
-0.26
0.18
0.05
0.26
-0.15
-0.04
0.00
-0.18
1.09
-0.41
-0.04
-0.69
-0.30
0.38
0.33
-0.49
0.16
0.29
0.07
-0.11
-0.15
0.16
-0.12
0.17
0.19
0.12
0.23
0.02

Table 3.6 (Continued)
Compound
Actual
pIC50
8.40
52
8.40
53
7.72
55
7.43
57
8.30
58
8.52
60
8.00
61
8.30
63
8.00
64
8.22
65
8.40
66
8.30
68
8.00
69
8.52
70
Test set
5.57
3
6.47
6
6.55
10
6.24
21
6.00
22
7.26
25
7.85
28
8.00
38
7.51
46
8.22
54
7.29
56
8.10
59
8.10
62
8.30
67

Predicted
pIC50
8.30
8.44
7.83
7.67
8.04
8.41
8.48
8.30
8.14
8.32
8.22
8.50
8.08
8.71

Residual

Residual

0.10
-0.04
-0.11
-0.24
0.26
0.12
-0.48
0.00
-0.14
-0.10
0.18
-0.20
-0.08
-0.19

Predicted
pIC50
8.42
8.45
7.55
7.57
8.12
8.28
8.30
8.31
8.17
8.42
8.45
8.64
8.31
8.79

6.14
5.96
6.03
5.93
6.12
7.35
6.61
7.95
7.61
7.89
7.75
7.96
8.26
8.44

-0.57
0.51
0.52
0.31
-0.12
-0.09
1.25
0.05
-0.10
0.34
-0.46
0.14
-0.16
-0.14

5.64
5.96
6.06
6.19
6.05
6.57
7.21
8.20
7.68
7.79
7.39
8.08
8.33
8.53

-0.07
0.51
0.49
0.05
-0.05
0.69
0.64
-0.20
-0.17
0.43
-0.10
0.02
-0.23
-0.23

-0.02
-0.05
0.17
-0.14
0.18
0.24
-0.30
-0.01
-0.17
-0.20
-0.05
-0.34
-0.31
-0.27

3.5 Summary of computational insights
The combined 3D-QSAR modeling and molecular docking resulted in valuable
insights into PDK1 binding with 70 inhibitors and their structure-activity correlation.
In this present study we first developed a 3D-QSAR model using ligand-based
alignment. We compared different alignment techniques and found that the
substructure based alignment method gives the best ligand-based 3D-QSAR model.
Use of higher-level optimization/charge calculation methods were reported to be
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able to reproduce the experimental structure.233 Hence in our present study, we
utilized PM3 for geometry optimization and the HF 6-31G* method for the charge
calculations. The drawback that could be expected for ligand-based 3D-QSAR
method is the difference between the template used for alignment and the real
bio-active conformation of the molecule. So we also performed receptor-based
3D-QSAR. We first performed a control run and checked the ability of different
docking programs to reproduce the three X-ray crystal structures of the ligands
binding with PDK1. We selected FRED-EM as the docking method to dock all the
ligands. Thus we have used different strategies to develop robust ligand-based and
receptor-based 3D-QSAR models. The models developed using both methods were
statistically valid with better q2, r2 values. Finally the models were also able to
predict the external test set of compounds which were not used in QSAR model
development. This shows the usefulness of the models in predicting the activity of
new compounds. Molecular docking revealed the detailed structures of PDK1
binding with the compounds. The interactions identified from the CoMFA and
CoMSIA 3D-contour maps correlate well with the specific interactions between the
inhibitors and the amino acid residues identified in the docked binding structures.
The fact that both methods gave similar results could point towards the general
usefulness of ligand-based approaches in cases where the target structure is not
available. Moreover, the combined modeling using two different approaches is a
better approach because it helps to overcome the error which may occur if we use
one particular method. The 3D contour maps obtained from the CoMFA and
CoMSIA models in combination with the detailed PDK1-inhibitor binding structures
obtained from molecular docking helped to better interpret the structure-activity
relationship of these PDK1 inhibitors and provide valuable insights into rational
drug design for further optimization of the biological activity of the PDK1
inhibitors.

Copyright © Mohamed Diwan Mohideen AbdulHameed 2009
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CHAPTER 4

4. HIT IDENTIFICATION: APPLICATION OF HIERARCHICAL VIRTUAL
SCREENING
Computational drug design approaches are used in both lead optimization and
hit/lead identification. As discussed before, PDK1 is a well known anti-cancer target
and application of such computational drug design approaches will help towards the
development of potent PDK1 inhibitors and ultimately lead to development of new
anti-cancer agents. In the previous chapters, we discussed the application of
computational lead optimization strategies against PDK1. We have used
structure-based lead optimization strategy for celecoxib and its derivatives. We have
used ligand-based and combined approaches in lead optimization of indolinone
derivatives. In both cases, previously known inhibitors were used as a starting point
to understand and design new PDK1 inhibitors. We were also interested in
identifying new compounds as PDK1 inhibitors. Computational virtual screening is
a very useful tool for hit identification. In this chapter, we discuss the application of
a hierarchical virtual screening strategy to identify hits against PDK1. Part of the
contents in chapter 4 was adapted from submitted article, AbdulHameed et al. J.
Comp. Aided Mol. Des. 2009.
4.1 Computational virtual screening approaches
Virtual screening methods are used for both lead identification and
optimization in various drug discovery projects.234 This method involves screening
a large database of millions of compounds using computational approaches and
selection of smaller number of compounds for final experimental testing.235 Virtual
screening is expected to reduce the amount of experimental work and has the
potential to reduce the cost and time of the initial drug discovery phase. This makes
virtual screening a very popular approach. A recent study comparing virtual
screening against experimental high-throughput screening (HTS) for the same target
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shows that virtual screening performs better than HTS. 236 A number of recent
studies have successfully identified new hits through virtual screening.237,238 Inspite
of its success, the current virtual screening approaches

have their own limitations

including consideration of the flexibility of active site residues during docking and
accurately accounting for the solvation/desolvation effects of protein-ligand
interaction.239 Many strategies have been proposed to improve the virtual screening
approaches.240,241 Screening strategies which use fast and quick filters in the initial
steps and more complex filters in later stages were reported to be better than simple
screening using one method. 242 The development of commercially available
compound database (ZINC) has further helped virtual screening applications by
reducing the time spent in preparing the databases.243 Recent research papers shows
that the performance of ligand-based virtual screening approach is faster and
perform better than simple docking methods.234 Absorption, Distribution,
Metabolism, and Excretion (ADME) properties were also reported to play a major
role in the development of a hit into a potential drug molecule.242 Application of
appropriate ADME filters in the early stage of virtual screening will help in
identifying a more suitable hit molecule. The computational binding free energy
calculation methods like linear interaction energy (LIE) and molecular
mechanics/Poisson-Boltzmann surface area (MM-PBSA) were reported to be useful
for the rapid estimation of the binding free energy of an inhibitor with the
macromolecular target.242 The MM-PBSA method has been successfully used for
calculating the binding free energies of protein-protein and protein-inhibitor
interactions.168 There are very few reports about the use of MM-PBSA method as a
part of virtual screening strategy to identify new lead molecules. One recent report
has shown the ability of MM-PBSA method to retain the known ligand when the
method is used as a part of virtual screening strategy.242 We are interested to analyze
the hierarchical virtual screening approach which uses a combination ligand-based
and structure-based approach along with the more sophisticated MM-PBSA method
as a final filter.
As PDK1 is a well validated and a promising anti-cancer target, we chose it
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as the target for our study. Identifying new hits as PDK1 inhibitor will help towards
the development of better treatment options for cancers. We have pursued an
efficient strategy of the hierarchical virtual screening with increasing complexity to
identify new hits against PDK1. We used ligand-based method ROCS

244,43

and

Rigid docking FRED245 as the initial filters followed by flexible docking using
FlexX 172 and finally molecular dynamics (MD) and MM-PBSA methods were used.
Applying hierarchical (step-wise) virtual screening strategy has helped us to identify
a nanomolar PDK1 inhibitor which is active in cell based anti-cancer screening.

4.2 Simulation methods
4.2.1 Preparation of database and protein
In this work we have used the ligand-based screening, rigid docking, flexible
docking, and molecular dynamics (MD) simulations followed by the MM-PBSA
calculations as screening filters in virtual screening. The flow chart of steps used in
our virtual screening strategy is given in Figure 4.1. The first step is the selection of
compound database and preparing protein structure for virtual screening. A subset of
Zinc 7 database243 containing 688,086 compounds was used in this study. Zinc
database represents an annotated database with curated molecules suitable for virtual
screening.243 The subset is made up of compounds from two major commercial
compound suppliers IBScreen (570,038 compounds) and Sigma Aldrich (115,588
compounds). We also included a subset of 2,460 FDA-approved drugs in our
screening dataset.
We chose to screen compounds from these two major vendors as it would be
convenient to purchase the compounds obtained as hits. We also included a natural
product database (2,900 compounds) built in our lab. This database was created
using resources like Comprehensive herbal medicinal information system for cancer
(CHMIS-C) database246 and other natural product literatures.247 Thus a total of
690,986 compounds were used for this virtual screening study.
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1
lead

Experimental
testing
MD Simulations/
MM-PBSA
Interaction energy and
Visual analysis

2
Compounds
120 Compounds

1,200 Compounds

Flexible Docking
(FLEXX)

3,500 Compounds

Rigid Docking
(FRED)

10,453 Compounds

Ligand based Screening
(ROCS)

157,623 Compounds + 33 Known inhibitors

PreScreening Filter
(FILTER)

690,986 Commercially available compounds
and in-house natural products database

Figure 4.1 Flowchart of the virtual screening strategy used in this study.

As discussed previously few X-ray crystal structures in the protein data bank
(PDB) are available for studying PDK1 binding with potential inhibitors. The
starting protein structure used in this study is the X-ray crystal structure of
adenosine-tri-phosphate (ATP) bound PDK1 (pdb code: 2BIY)101. The missing side
chain atoms of residues Gln73, Arg75, Glu153, Lys228, Arg238, Lys304, Glu343,
Glu348, and Lys357 were modeled using Sybyl 7.0 program. We decided to use a
known inhibitor, i.e. BX-320,111 as the bound ligand. The obtained complete protein
structure binding with BX-320 was used to carry out an MD simulation. The final
stable, MD-simulated structure was used as the initial structure for our virtual
screening study.

4.2.2 Pre-screening filter
The entire database was filtered with FILTER v.1.1.1 (OpenEye scientific
software,

www.eyesopen.com)

to

eliminate

inappropriate

or

undesirable

compounds.248 The Filter is a molecular screening tool that uses a combination of
physical property calculations and functional group knowledge to assess libraries
and ultimately remove non-lead-like compounds.241 Physical properties, atomic or
94

functional group content, and molecular graph topology are the three categories used
by this program to allow or remove a given molecule in the database. The default
lead-like filter available in this program was used with some minor variations. The
main parameters that we used involve: molecular weight (minimal value = 150 Da,
Maximum value = 440 Da, and rings (min=0, max=3), rotatable bonds (min=0,
max=10), allowed elements (H, C, N, O, F, S, Cl, and Br), hydrogen bond donor
(max=6), hydrogen bond acceptor (max=10). We filtered out molecules with XlogP
greater than 4.0, which violates more than one Lipinski rule of five or if it is a
known aggregator. Predicted aggregator and GSK_VEBER calculation which is
present in the default script was not used in our study. The resulting library
contained 157,623 compounds in mol2 format. The Filter input file used in this
study is given in Appendix A.

4.2.3 Control data set
In order to check the nature of the run and to evaluate the process, we added a
control dataset of 33 known PDK-1 inhibitors. 17 compounds were collected from
various scientific reports [109, 110, 111,211, 212 ,249] and 16 compounds from
patent applications [250,251,252,253,254]. Thus a total of 33 known inhibitors were
used as the control set to quantify the performance of the virtual screen run. To
evaluate the performance of the virtual screening run, hit rate and enrichment factor
suggested by Wang et al.242 were calculated by using Eqs.(1) and (2):
Hit Rate =

Number of known inhibitors that passed the filter
Total number of known inhibitor in the database

Enrichment Factor = Hit Rate ×

(4-1)

Number of compounds in the database
(4-2)
Number of compounds that passed the filter

Enrichment factor is a commonly used metric in virtual screening run.255 The higher
the enrichment factor, the better the performance of a virtual screening run is. The
enrichment factor indicates that the final database obtained after the screening is
enriched with the active compounds compared to the initial database where it is
randomly scattered.255
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4.2.4 Conformer Generation
We first generated multiple conformations of each ligand in the database by
using OMEGA. 256 OMEGA is a systematic conformer generation tool. The
algorithm implemented in OMEGA has two main components: 1) model building
and 2) torsion driving. It dissects the molecule into fragments and generates
fragment library. The molecules were then reassembled from the fragments.
Molecular assembly is accomplished by simple vector alignment. By reassembling
the fragments, it regenerates many possible combinations and submits each
conformer to a simplified energy evaluation. Then all conformers below an energy
threshold were compared and those within a certain RMS distance are clustered into
a single representation. Atom typing, energy calculations, and geometry
optimization in OMEGA were performed using the Merck Molecular Force Field
(MMFF). The maximum allowed conformations per compound was set to 400 and
the energy window (the value used to discard high-energy conformations) was set to
10 kcal/mol. The default values of OMEGA program were used for other
parameters.

4.2.5 Filter-1 (Ligand-based virtual screening)
Shape-based screening was used as the first filter in our virtual screening. The
program ROCS was used.244,43 It was used to find the similarity between the
molecules based on their shape. The basic idea behind ROCS is that two objects
cannot have the same shape if their volumes are not the same. This method tries to
find and quantify the maximal overlap of the volume of two molecules. The goal of
this method is to find molecules that can adopt shapes extraordinarily similar to the
query without necessarily having similar atom types and bonding patterns.43 So
molecules are optimally aligned and matches are based on the volume overlap.
Similarity is quantitated by shape Tanimoto. This shape Tanimoto has quantity 1.0
if two shapes are identical, and 0.0 if completely different. In the present work
ROCS shape searching with chemical complementarity is used. The chemical
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complementarities searches used the ImplicitMillsDean chemical forcefield, (also
called color forcefield) which defines six chemical types: hydrogen-bond donors,
hydrogen-bond acceptors, hydrophobes, anions, cations, and rings. Both shape
Tanimoto and color forcefield were used in the ranking of ligands by ROCS.
From the 157,623 compounds, a multi-conformational database was generated
using the OMEGA and screened with ROCS. We utilized the co-crystallized
structures of 3 PDK1 inhibitors from PDB databank as the ligand query and selected
the top ~2.5% (4000) hits for each query. The three ligand queries have three
different scaffolds including amino-pyrimidine, bisindolylmaleimide, and indolinone
and were retrieved from PDB IDs: 1Z5M, 1UU3, and 1PEO respectively.109,111,211

4.2.6 Filter-2 (Rigid docking)
FRED (OpenEye Scientific Software) docking calculations were carried out
using protein structures with all hydrogen atoms and with the binding site definitions
provided by FRED Receptor program (OpenEye Scientific Software).245 FRED
docking roughly consisted of two steps, i.e. shape fitting and optimization. During
the shape fitting, the ligand was placed into a 0.5 Å-resolution grid box
encompassing all active-site atoms (including hydrogen atoms) using a smooth
Gaussian potential.220
FRED carries out exhaustive docking of multi-conformer ligand and generation
of poses. The pose ensemble was then filtered to reject poses that do not have
sufficient shape complimentarity to the protein’s active site followed by rejection of
poses that do not have at least one heavy atom in adenine pocket near Leu212. The
top-ranked poses are optimized by solid body optimization and refined with MMFF
forcefield. Preliminary docking trials led us to select OEchemscore for the
optimization filters.

4.2.7 Filter-3 (Flexible docking)
We also analyzed docking using FlexX module of SYBYL. The active site was
defined as residues within 6.5 Å around the bound ligand. Based on the crystal
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structure, the region with residues Leu88, Val96, Leu212, Ala162, and Lys111 were
defined as the core sub-pocket. The ligands were docked using the multiple-ligand
docking option of the FlexX.

4.2.8 Molecular dynamics in vacuum
We further refined the PDK1-ligand binding structures with the energy
minimization followed by a 20-ps MD simulation at T = 298.15 K for each binding
structure. The energy minimization was performed by using the steepest descent
algorithm first until the maximum energy derivative was smaller than 4 kcal/mol/Å
and then using the conjugated gradient algorithm until the maximum energy
derivative was smaller than 0.001 kcal mol-1 Å-1. During the energy minimization
and MD simulation, only the ligand and residue side chains in the binding pocket
were kept free to move. The nonbonded interaction cutoff and the dielectric constant
were set up to group-based (20-Å cutoff distance) and distance-dependent ( =
4r)227,257 to mimic the solvent environment, respectively. The MD simulation was
performed by using Amber8 program with a time step of 1 fs.

4.2.9 Molecular dynamics in water
The general procedure for carrying out the MD simulations in water is
essentially the same as that used in our earlier computational studies in chapter 2.
Briefly, the MD simulations were performed using Sander module of Amber8
program.184 The partial atomic charges for the ligand atoms were calculated using
the RESP protocol185 after electrostatic potential calculations at Hartree-Fock (HF)
level with 6-31G* basis set using Gaussian03 program.186 The PDK1-ligand binding
complex was neutralized by adding appropriate counter ions and was solvated in a
rectangular box of TIP3P water molecules187 with a minimum solute-wall distance
of 10 Å. The solvated systems were carefully equilibrated and fully
energy-minimized. These systems were gradually heated from T = 10 K to T =
298.15 K in 35 ps before a production MD simulation run. The time step used for
the MD simulations was 2 fs. Periodic boundary conditions in the NPT ensemble at
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T = 298.15 K with Berendsen temperature coupling188 and P = 1 atm with isotropic
molecule-based scaling were applied. The SHAKE algorithm was used to fix all
covalent bonds containing hydrogen atoms.189 The particle mesh Ewald (PME)
method190 was used to treat long-range electrostatic interactions. Restrain was
placed on the C-alpha backbone atoms during the MD run. A residue-based cutoff of
12 Å was utilized to the non-covalent interactions. Production MD was then carried
out for 1 nanosecond (ns) or more with 2 fs time step. The time-dependent geometric
parameters were carefully examined to make sure that we obtained a stable MD
trajectory for each simulated protein-ligand binding system. The coordinates of the
simulated system were collected every 1 ps during the simulation. 100 snapshots of
the simulated structure within the stable MD trajectory were used to perform the
MM-PBSA calculations.

4.2.10 Binding free energy calculation
The binding free energies were calculated by using the molecular
mechanics-Poisson-Boltzmann surface area (MM-PBSA) free energy calculation
method.168 The MM binding energies were calculated with the Sander module of
Amber8 program. Electrostatic solvation free energy was calculated by the
finite-difference

solution

to

the

Poisson–Boltzmann

equation

(∆GPB)

as

implemented in the Delphi program.192 The radius used for the solvent probe is 1.4 Å.
The MSMS program195 was used to calculate the SASA for the estimation of the
non-polar solvation energy (∆Gnp) using with the default parameters, i.e. γ = 0.00542
kcal/Å2 and β = 0.92 kcal/mol. Further, the entropic contribution, -T∆S, to the
binding free energy was also calculated at T = 298.15 K by using the NMODE
module of Amber8 program which is based on a combination of the standard
classical statistical formulas and normal mode analysis.196,197 The final binding free
energy calculated for each protein-ligand binding mode was taken as the average of
the ∆Gbind values calculated for the 100 snapshots.
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4.2.11 PDK1 kinase assay
The in vitro kinase assays were performed using the Invitrogen PDK1 assay kit
(P2884) according to vendor’s instructions. This assay was based on the ability of
recombinant PDK1, in the presence of DMSO or the inhibitor, to phosphorylate its
substrate peptide (P2925). These phosphopeptides generated during the kinase
reaction of PDK1 competes with the fluorescein-labeled phosphopeptides (called as
tracer) for binding to anti-phosphothreonine peptide-specific antibodies. This
binding is then quantified using fluorescence polarization (FP) technique. FP value
was measured using TECAN GENIOS PRO microplate reader.

4.2.12 Cell-based assay
The most active compounds in the kinase assay were submitted to the
developmental therapeutics program (DTP) at national cancer institute (NCI).258, 259
The compounds are screened against 60 human cancer cell lines. In the NCI screen,
60 human cancer cell lines were treated 48 h with 10-fold dilutions of compounds at
a minimum of five concentrations (0.01 to 100 μM). The screening was done using a
sulforhodamine B protein assay to estimate the cell viability or growth. Using seven
absorbance measurements [time zero, (Tz), Control growth, (C), and test growth in
the presence of drug at five different concentration levels (Ti)], the percentage
growth was calculated at each of the drug concentration levels. The percentage
growth was calculated as: [(Ti-Tz)/(C-Tz)]* 100.258
4.3 Hierarchical virtual screening analysis and identification of new hits
We have used rapid and lower level methods at the beginning and turned to
the more accurate and quantitative methods at the end. In this prospective analysis,
we have utilized a subset of 688,086 commercially available inhibitors from Zinc
database. In addition to screening commercially available compounds, we included
another promising strategy in lead identification, namely the virtual screening of
natural products. Natural products are a source of diverse chemical compounds. So
we also included an in-house database of 2,900 natural products. Thus a total of
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690,986 compounds were subjected to the virtual screening study.

4.3.1 Pre-screening filter & control dataset
We applied the physicochemical property filters (ADME/Tox, Lipinski’s rule of
five) as the first step (pre-screening filter). The overall reasoning is that it is better to
focus on identifying new leads with good potencies as well as good ADMET and
pharmacokinetic properties. Previous reports have suggested that it would be more
beneficial if we analyze the datasets for drug-like property at the beginning of the
virtual screen run.242 False positives are one of the major problems in virtual screen
run. Removing the non-drug like molecule will also help to improve the screening
efficinecy and time. We used the lead-like filter with the FILTER software from
OpenEye. It was used to remove compounds with reactive functional groups,
compounds that violate more than one Lipinski rule of five, exceeding a maximum
2-dimensional polar surface area etc. Thus we initially eliminated inappropriate or
undesirable compounds from the dataset. Application of this pre-screening filter to
the initial dataset of 690,986 compounds gave a final dataset of 157,623 compounds.
The pre-filtered database of 157,623 compounds was used as the starting point
for this virtual screening study. Our aim was to perform a prospective analysis to
identify new PDK1 inhibitors. In order to check the nature of the run and to evaluate
the process, we added a control dataset of 33 known PDK-1 inhibitors reported in
literature and patents.

4.3.2 Ligand-based virtual screening
Recent reports have shown the success ligand-based virtual screening method
such as ROCS in identifying the known inhibitors and in new lead identification.43
Because of its speed and good performance in previously reported virtual screening
studies, 260,261 ROCS was chosen as the filter for the first ligand-based virtual
screening filter. We used three different scaffolds as the query molecule in ROCS.
The reason for using three different scaffolds simultaneously is that the choice of the
ligand molecule will have a critical effect on the results from ligand-based screening
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and the use of diverse ligands but in their native state will help us to overcome the
bias of using any one ligand as the query molecule. Moreover it has been reported
that the better enrichment can be obtained by using more than one query
simultaneously.262 By selecting the top 4,000 (~2.5%) most similar compounds to
the query ligands in this filter we got a total of 12,000 compounds. Removing the
repeated structures gave us a total of 10,431 final compounds. This filter was able to
retain 28 of the 33 known inhibitors. The hit rate for this step was 85% and the
enrichment factor was 12.84. The enrichment factor of ~13 means that we have a
13-fold higher chance to find a real inhibitor in this filtered dataset than from the
initial database.

4.3.3 Rigid & Flexible docking
The results from ROCS were subjected to rigid docking using the FRED
software from OpenEye. This step is more sophisticated than Filter-1 as it introduces
the active site shape in the screening. Since it performs rigid docking, conformations
have to be generated again for the hits from ROCS. OMEGA was used to generate
the conformations using the default values. On average, 30 conformations were
generated per molecule. FRED docking involves exhaustive docking of
multi-conformer ligand and generation of poses. OEChemscore was used in the
selection of hits. A total of 3,500 compounds were obtained by using the score cutoff
of -32.6. 22 known inhibitors were found in this filtered set. The hit rate for this step
is 76%. The hit rate for the first two filters together was 66% and the enrichment
factor was 29.7
Next we carried out flexible docking using FlexX. In this method, the ligand
was treated as flexible and the receptor was held rigid. The FlexX uses anchor and
grow strategy to account for flexible ligand docking. Selecting the top 1,200
compounds from FlexX docking gave us a final set of 1,200 compounds. 19 known
inhibitors were found in this final set. The hit rate for this step is 86%. The hit rate
for the three filters together was 58% and the enrichment factor was 76.2. This
means that we have ~76-fold higher chances to find a real inhibitor in this final
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dataset (obtained after three filters) than from whole database.

4.3.4 Refinement through interaction energy calculation and visual analysis
To further refine the result, the docked ligands were refined by MD simulations in
vacuum. The interaction energies (vdw and electrostatic) of PDK1-ligand complexes
were used along with visual analysis and refinement. It should be noted that the
active site of PDK1 as well as all known kinases can be divided into 3 regions,
namely the adenine pocket, sugar pocket, and phosphate pocket.112 In order to refine
the hits, the compounds that did not fit into the adenine pocket were removed first.
We also checked whether there are common chemical features present in the known
PDK1 inhibitors, as this could help us in further refining the hits. Superposition of
the available PDK1-inhibitor X-ray crystal structures showed that all the inhibitors
had a common hydrogen bond acceptor (in the same position) which interacts with
the backbone NH group of Ala162 in the hinge region. Some inhibitors have an
additional hydrogen bond interaction with the backbone carbonyl group of Ala162.
Based on these observations, we removed the compounds that have very low
binding affinity (i.e. high interaction energy) and that do not have at least one
interaction with either i) the backbone -NH group of Ala162 or ii) with the backbone
carbonyl group of Ala162 in the hinge region or iii) with Lys111 residue. 120 hits
were selected from this process and were further refined using molecular dynamics
simulations and MM-PBSA analysis discussed below.

4.3.5 Molecular dynamics simulations and Binding free energy calculations
Our final filter made use of molecular dynamics simulations and binding free
energy calculations. Explicit water molecules were used in the molecular dynamics
simulation. The ligands and the side chains of the protein were all flexible during
this solvated molecular dynamics run for ~1.0 ns. The docked molecules that have
stable MD trajectories were selected for further analysis. The binding free energy
was calculated using the MM-PBSA method. The compounds having MM-PBSA
scores better than -7.0 kcal/mol was chosen as the final hit set. From this hit list, two
103

compounds were cherry picked (based on the commercial availability or ease of
synthesis) for initial experimental testing. The compound chosen for wet
experimental

study,

is

ethyl-4-[[2-[-(4-ethoxycarbonylphenyl)amino]

-6-methylpyrimidin-4yl]amino] benzoate (1) which can be purchased from Analogix,
Inc. (Burlington, WI). The other compound is (2) which had to be synthesized in
house, as it belongs to the natural product database and it was not commercially
available.

4.3.6 PDK1 assay
Compound 1 was purchased from Analogix, Inc. (Burlington, WI).
Compound 2 belongs to natural product database and was not commercially
available. It was synthesized by our colloborator Dr. Wei Wang at University of New
Mexico. Mr. Wenchao Yang in our lab carried out the wet experimental tests. Wet
experimental tests on the inhibitory activities of the identified compounds were
carried out using fluorescence polarization assays. We carried out the PDK1 assays
along with a standard reference (Staurosporine) in order to make sure that the
inhibitory activity data obtained for the two compounds are comparable to the
previously reported inhibitory activity of known compound. Our experimental tests
revealed that both compounds 1 and 2 can significantly inhibit PDK1. According to
the activity data, we obtained IC50 = ~200 nM for compound 1 and IC50 = ~20 µM
for compound 2. The natural product compound 2 is norathyirol, the aglycone of
mangiferin. Thus by starting with a database of 690,986 molecules, we were able to
obtain two new inhibitors of PDK1, by combining sequential virtual screening with
experimental testing.

4.3.7 Cell-based assay
For a successful hit it is also important for the compound to be active in
cell-based assay. So the activity of the identified PDK1 inhibitors was analyzed
further in the cell-based assays. The compound was submitted to the NCI DTP for
the 60 cancer cell lines screening. The new PDK1 inhibitors was found to
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significantly inhibit many cancer cell lines. When tested at 10 micromolar
concentration, norathyriol was found to have a significantly lower inhibitory activity
than compound 1. This is qualitatively consistent with our PDK1 inhibition data.
The inhibition data of the new compound against 4 selected cell lines was shown in
Figure 4.5. Our new lead compound 1 also effectively inhibit many cancer cell lines,
such as multiple myeloma cell line RPMI8226, non non-small cell lung cancer cell
line HOP92, colon cancer cell line KM12, CNS cancer cells SF268, Melanoma cell
LOX IMVI, Ovarian cancer cells OVCAR-3, Renal cancer cells RXF 393, Prostate
cancer cell line PC-3, and Breast cancer cell line HS578T. The growth inhibitory
activity of compound 1 against various cell lines are given in Table 4-2.

4.3.8 Binding mode of new hits
Understanding the binding mode of this new PDK1 inhibitor will be of great
help in further lead optimization studies. Figures 4.3 and 4.5 shows the binding
mode of the hits with PDK1. The compound 1 has a hydrogen bond interaction with
the backbone carbonyl group of Ala162 in the hinge region. The pyrimidine ring is
present in the hydrophobic adenine pocket of PDK1. It is surrounded by residues
Leu212 and Leu88. There is another hydrogen bond interaction between the
backbone carbonyl group of Leu88 and the –NH group of the inhibitor. The ester
group is present in the sugar region in the pocket does not interact with any specific
residue. Based on the PDK1-inhibitor binding modes, the identified PDK1 inhibitor
may be used as new starting point in future de novo drug design and discovery
efforts.
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Figure 4.2 Molecular structures of new hits identified through virtual screening.

Table 4.1 Binding free energies (kcal/mol) calculated at T = 298.15 K and P = 1 atm
for PDK1 binding with representative inhibitors in comparison with the
corresponding experimental data.
Calc.a

Inhibitor

Expt.
ΔEMM
ΔGsol
-TΔS
∆Gbind
∆Gbind
b
Celecoxib
-56.5
40.1
11.3
-5.1
-5.9
-59.6
35.5
12.5
-11.5
-9.1
Compound 1
-81.3
59.8
13.3
-8.2
-6.4
Compound 2
a
The MM-PBSA calculations were performed on 100 snapshots along a stable MD
trajectory for each PDK1-inhibitor binding complex. The results given in the table
are the average values calculated for the 100 snapshots. b The data for celecoxib was
reported in reference [136].
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(A)

1

(B)

1

Figure 4.3 Binding of compound 1 in the PDK1 active site. Compound 1 is shown
in sticks with carbon atoms in green color.

2

Figure 4.4 Binding of compound 2 in the PDK1 active site. Compound 2 is shown
in sticks with carbon atoms in green color.
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Figure 4.5 Growth inhibitory effect of compound 1 against representative cancer
cell lines
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Figure 4.6 Plots of MD-simulated internuclear distances versus simulation time for
PDK1 binding with compound 1. D1 refers to the distance between N1 atom of
compound 1 and the carbonyl oxygen of Ala162 backbone, D2 the distance between
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N3 atom of compound 1 and the carbonyl oxygen of Leu88 backbone, and D3 the
distance between N4 atom of compound 1 and the carbonyl oxygen of Leu88
backbone.
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Figure 4.7 Plots of MD-simulated internuclear distances versus simulation time for
PDK1 binding with compound 2. D1 refers to the distance between O4 atom of
compound 2 and the NH nitrogen of Ala162 backbone, D2 the distance between O3
atom of compound 2 and the carbonyl oxygen of Ser160 backbone, and D3 the
distance between O2 atom of compound 2 and the hydroxyl oxygen of Thr222
sidechain.
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Table 4.2 Growth inhibitory activity of compound 1a against various cell lines in
NCI human cancer cell line panel
No. Cell Line (Panel name)
GI50
(μM)
1.
RPMI-8226
3.54
(Leukemia)
2.
HOP-92
3.25
(Non-Small cell Lung Cancer)
3.
KM12
3.62
(Colon Cancer)
4.
SF-268
3.80
(CNS cancer)
5.
SF-295
8.64
(CNS Cancer)
6.
U251
9.88
(CNS Cancer)
7.
LOX IMVI
7.24
(Melanoma)
8.
OVCAR-3
2.02
(Ovarian Cancer)
9.
RXF 393
5.05
(Renal Cancer)
10. PC-3
6.02
(Prostate Cancer)
11. DU-145
5.39
(Prostate Cancer)
a

Data obtained from the NCI-DTP’s in-vitro human cancer cell line screen259
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4.4 Key Findings
A hierarchical virtual screening strategy has been tested and employed to
identify new lead compounds against PDK1. We utilized the fast filtering, such as
ligand-based screening in the beginning, and carried out the more sophisticated
MD/MM-PBSA analysis as a final filter in the virtual screening. The virtual
screening of 690,986 compounds eventually led to the selection of five compounds
for wet experiments. Among the five compounds selected for wet experiments, two
compounds were found to significantly inhibit PDK1. We also used a control dataset
to evaluate the virtual screening run. The hit rate and the enrichment factor for the
first three filtering steps were found to be 58% and 76.2, respectively. Thus, using
virtual screening stratgey combined with the MD simulations and MM-PBSA
binding energy analysis, we were able to identify new hits for PDK1 with reduced
the amount of experimental efforts. The compounds identified in this study serves as
a good starting point for future rational drug design of PDK1 inhibitors. Our virtual
screening approach may also be applied in discovery of new lead molecules for
other drug targets.

Copyright © Mohamed Diwan Mohideen AbdulHameed 2009
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CHAPTER 5

5. SUMMARY AND FUTURE DIRECTIONS
Computational drug design approach has a great potential in accelerating the
drug discovery process. Structure-based drug design and ligand-based drug design
are the two broad classes of computational drug design. PDK1 is a well validated
anti-cancer target and developing inhibitors for PDK1 has the potential to be
developed as the anti-cancer therapeutics. In this work, we have showed the
potential of computational approaches in drug discovery using PDK1 as our target.
We have used both structure-based and ligand-based drug design strategies as well
as combined approaches for lead optimization and hit identification against PDK1.
In our structure-based lead optimization, we used celecoxib and its derivatives
as our lead molecules. For any structure-based drug design study it is crucial to
know whether the proposed binding mode is reasonable or not for future rational
drug design. Understanding the molecular basis of interaction is essential to carry
out structure-guided lead optimization. One cannot expect to have success in a
computational drug design starting with a wrong binding mode. In order to find the
reasonable microscopic binding mode for PDK1 binding with celecoxib and its
derivatives, we carried out molecular docking, followed by molecular dynamics
simulations, and found a totally new binding mode. Since different docking
programs gave different results, we used more sophisticated computational
techniques like molecular dynamics simulations and MM-PBSA binding free energy
calculations. For all of the representative PDK1 inhibitors examined in this study,
based on the most favorable binding modes, the calculated binding free energies
were all in good agreement with the corresponding experimental activity data. The
determined new, more favorable binding mode can explain the SAR for this series of
inhibitors.
Another significant contribution is that we have showed for the first time that the
novel binding mode without the hydrogen bond interaction in the hinge region is
possible for a kinase inhibitor. It will be interesting to analyze in future studies
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whether absence of such interaction contributes to the selectivity of the inhibitors
against different kinases. Further exploring this type of inhibitors for other kinases
has the potential to find new class of inhibitors which will help to overcome
crowded intellectual property rights in this field. Moreover we have also shown that
only performing simple molecular docking could lead to a wrong binding mode and
thus mislead the rational drug design. The computational protocol tested in this study,
i.e. the molecular docking followed by the combined MD simulations and
MM-PBSA calculations, is reliable and accurate for predicting protein-ligand
binding structures and binding free energies. This protocol could be used in other
drug discovery efforts.
We have also carried out ligand-based lead optimization using indolinone
derivatives as our lead molecule. We have developed both ligand-based and
receptor-based 3D-QSAR models. This analysis led to the development of
satisfactory 3D-QSAR models for predicting the biological activity of new
compounds. Our models were able to predict the activity of external test set of
compounds which were not used in model development. All of the results obtained
from the 3D-QSAR analysis and molecular docking are consistent with the
experimental activity data. Since Indolinone is one of the ten most frequently
encountered sub-structures in kinase inhibitors, our 3D-QSAR models have the
potential to predict and guide the rational design of new ligands of indolinone series
as PDK1 inhibitors. We have also showed that the usefulness of ligand-based models.
The contour plots obtained from the ligand based models is consistent with the
receptor active site. There are many therapeutic targets which do not have the
experimentally determined structures. Our study shows that the ligand-based
approaches like CoMFA have the potential to give insight into the nature of the active
site of the targets in such cases.
We have used hierarchical virtual screening of increasing complexity to
identify new hits against PDK1. We have used the ligand-based screening, rigid
docking, flexible docking, and molecular dynamics (MD) simulations followed by
the MM-PBSA calculations as screening filters in virtual screening. Using this
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strategy we have identified a promising new hit for the development of a novel
anticancer therapeutic. The inhibitor identified in this study serves as a good starting
point for future rational drug design of PDK1 inhibitors. Our virtual screening
approach may also be applied to discovery of new lead molecules for other drug
targets.
De novo drug design can be carried out starting from the new hit identified from
virtual screening. The computational design can be followed by chemical synthesis
and in vitro enzyme inhibition assays for the inhibitory activity and selectivity. The
inhibitors can be tested for their anticancer activities in vitro. Further extensive
retrospective validation of the shape-based virtual screening approaches and
hierarchical virtual screening approaches can be done. Such large-scale validation
using already known inhibitors will help to prove the applicability of this approach in
a wide variety of target and also document potential advantages and limitations of this
approach.
The insights obtained from this research work can also be applied in new drug
discovery projects against other therapeutic targets. The different scenarios for new
projects include: 1) projects where the experimentally solved structure of target is
available; 2) experimentally solved structure of target is not available but structure of
related protein (which can serve as template) is available; 3) structures of target and
template are not available; 4) experimentally solved structure of target is not available
but ligands of target available. In the first case, when the X-ray crystal structure of the
target is available, we may carry out structure-based drug design by using the same
procedures as we used in this project. Specifically, we may carry out virtual screening
and de novo design for discovery of new inhibitors. If the experimentally solved
structure is not available but the X-ray structure of a related protein (template) is
available, then we can carry out homology modeling of the target structure using the
template structure. The modeled protein structure will serve as the starting point for
structure-based drug design. Then we may follow the same strategies used in this
present work, namely virtual screening and de novo design, using the modeled target
structure. In the third scenario, i.e. when both the target structure and template
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structure are all unavailable, it might be possible to perform ab initio prediction of the
target protein structure, as our lab did for anti-inflammatory target mPGES-1.46
Site-directed mutagenesis experiments may be performed to validate the 3D structure
resulted from the ab initio protein structure prediction. If the 3D structure is consistent
with the experimental studies, then it is reasonable to use the 3D structure for further
computational drug design as described above. Finally, if we have to work on a new
project without any experimentally solved structure of the target but if there are
known ligands of the target, then we may utilize ligand-based drug design strategies
as we have done in this work (chapter 3). Ligand-based 3D-QSAR methods like
CoMFA and CoMSIA can be utilized to understand the structure-activity relationship
and to aid in the design of new inhibitors of this series. The contour plots can also be
used to get insights into the nature of the target active site as we have shown in our
studies. 201,206
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APPENDIX I Filter used in virtual screening
# FILTER used in PDK1 virtual screening run
#/**********************************************************************
#Copyright (C) 2000-2005 by OpenEye Scientific Software, Inc.
#***********************************************************************
#This file defines the rules for filtering multi-structure files based on properties and substructure
#patterns.
MIN_MOLWT
150
"Minimum molecular weight"
MAX_MOLWT
440
"Maximum molecular weight"
MIN_NUM_HVY
MAX_NUM_HVY

10
35

"Minimum number of heavy atoms"
"Maximum number of heavy atoms"

MIN_RING_SYS
MAX_RING_SYS

0
3

"Minumum number of ring systems"
"Maximum number of ring systems"

MIN_RING_SIZE
MAX_RING_SIZE

0
20

"Minimum atoms in any ring system"
"Maximum atoms in any ring system"

MIN_CON_NON_RING
MAX_CON_NON_RING
MIN_FCNGRP
MAX_FCNGRP

0
15

0
12

MIN_UNBRANCHED
MAX_UNBRANCHED
MIN_CARBONS
MAX_CARBONS

MIN_Het_C_Ratio
MAX_Het_C_Ratio

"Minimum number of functional groups"
"Maximum number of functional groups"

0
3
5
35

MIN_HETEROATOMS
MAX_HETEROATOMS

"Minimum number of connected non-ring atoms"
"Maximum number of connected non-ring atoms"

"Minimum number of connected unbranched non-ring atoms"
"Maximum number of connected unbranched non-ring atoms"
"Minimum number of carbons"
"Maximum number of carbons"

2
12

0.10
1.1

MIN_HALIDE_FRACTION
MAX_HALIDE_FRACTION

"Minimum number of heteroatoms"
"Maximum number of heteroatoms"
"Minimum heteroatom to carbon ratio"
"Maximum heteroatom to carbon ratio"
0.0
0.5

"Minimum Halide Fraction"
"Maximum Halide Fraction"

#count ring degrees of freedom = (#BondsInRing) - 4 - (RigidBondsInRing) (BondsSharedWithOtherRings)
#must be >= 0, from JCAMD 14:251-265,2000.
ADJUST_ROT_FOR_RING
true
"BOOLEAN for whether to estimate degrees of
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freedom in rings"
MIN_ROT_BONDS
MAX_ROT_BONDS

0
10

MIN_RIGID_BONDS
MAX_RIGID_BONDS

"Minimum number of rotatable bonds"
"Maximum number of rotatable bonds"

0
25

"Minimum number of rigid bonds"
"Maximum number of rigid bonds"

MIN_HBOND_DONORS 0
MAX_HBOND_DONORS 4

"Minimum number of hydrogen-bond donors"
"Maximum number of hydrogen-bond donors"

MIN_HBOND_ACCEPTORS 0
MAX_HBOND_ACCEPTORS 6

"Minimum number of hydrogen-bond acceptors"
"Maximum number of hydrogen-bond acceptors"

MIN_LIPINSKI_DONORS 0
MAX_LIPINSKI_DONORS 5

"Minimum number of hydrogens on O & N atoms"
"Maximum number of hydrogens on O & N atoms"

MIN_LIPINSKI_ACCEPTORS 0
MAX_LIPINSKI_ACCEPTORS 10
MIN_COUNT_FORMAL_CRG
MAX_COUNT_FORMAL_CRG
MIN_SUM_FORMAL_CRG
MAX_SUM_FORMAL_CRG

0
3

-2
2

"Minimum number of oxygen & nitrogen atoms"
"Maximum number of oxygen & nitrogen atoms"
"Minimum number formal charges"
"Maximum number of formal charges"
"Minimum sum of formal charges"
"Maximum sum of formal charges"

MIN_CHIRAL_CENTERS
chiral centers"
MAX_CHIRAL_CENTERS
"Maximum chiral centers"
MIN_XLOGP
MAX_XLOGP

-5.0
4.0

0

"Minimum
4

"Minimum XLogP"
"Maximum XLogP"

#choices are insoluble<poorly<moderately<soluble<very<highly
MIN_SOLUBILITY
moderately
"Minimum solubility"
PSA_USE_SandP
MIN_2D_PSA
MAX_2D_PSA

false
0.0
150.0

AGGREGATORS
#PRED_AGG

true
true

"Count S and P as polar atoms"
"Minimum 2-Dimensional (SMILES) Polar Surface Area"
"Maximum 2-Dimensional (SMILES) Polar Surface Area"
"Eliminate known aggregators"
"Eliminate predicted aggregators"

#secondary filters (based on multiple primary filters)
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#GSK_VEBER
true
"PSA>140 or >10 rot bonds"
MAX_LIPINSKI 1
"Maximum number of Lipinski violations"
MIN_ABS 0.5
"Minimum probability F>10% in rats"
PHARMACOPIA
true
"LogP > 5.88 orPSA > 131.6"
ALLOWED_ELEMENTS H,C,N,O,F,S,Cl,Br
ELIMINATE_METALS Sc,Ti,V,Cr,Mn,Fe,Co,Ni,Cu,Zn,Y,Zr,Nb,Mo,Tc,Ru,Rh,Pd,Ag,Cd
#acceptable molecules must have <= instances of each of the patterns below
#specific, undesirable functional groups
RULE 0 quinone
RULE 0 pentafluorophenyl_esters
RULE 0 paranitrophenyl_esters
RULE 0 HOBT_esters
RULE 0 triflates
RULE 0 lawesson_s_reagent
RULE 0 phosphoramides
RULE 0 beta_carbonyl_quat_nitrogen
RULE 0 acylhydrazide
RULE 0 cation_C_Cl_I_P_or_S
RULE 0 phosphoryl
RULE 0 alkyl_phosphate
RULE 0 phosphinic_acid
RULE 0 phosphanes
RULE 0 phosphoranes
RULE 0 imidoyl_chlorides
RULE 0 nitroso
RULE 0 N_P_S_Halides
RULE 0 carbodiimide
RULE 0 isonitrile
RULE 0 triacyloxime
RULE 0 cyanohydrins
RULE 0 acyl_cyanides
RULE 0 sulfonylnitrile
RULE 0 phosphonylnitrile
RULE 0 azocyanamides
RULE 0 beta_azo_carbonyl
RULE 0 polyenes
RULE 0 saponin_derivatives
RULE 1 cytochalasin_derivatives
RULE 4 cycloheximide_derivatives
RULE 1 monensin_derivatives
RULE 1 squalestatin_derivatives
#functional groups which often eliminate compounds from consideration
RULE 0 acid_halide
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RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE
RULE

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

aldehyde
alkyl_halide
anhydride
azide
azo
di_peptide
michael_acceptor
beta_halo_carbonyl
nitro
oxygen_cation
peroxide
phosphonic_acid
phosphonic_ester
phosphoric_acid
phosphoric_ester
sulfonic_acid
sulfonic_ester
tricarbo_phosphene
epoxide
sulfonyl_halide
halopyrimidine
perhalo_ketone
aziridine
oxalyl
alphahalo_amine
halo_amine
halo_alkene
acyclic_NCN
acyclic_NS
SCN2
terminal_vinyl
hetero_hetero
hydrazine
N_methoyl
NS_beta_halothyl
propiolactones
nitroso
iodoso
iodoxy
noxide

#groups of molecules
RULE 2 dye
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#functional groups which are allowed, but may not be wanted in high quantities
#common functional groups
RULE 6 alcohol
RULE 4 alkene
RULE 4 amide
RULE 4 amino_acid
RULE 2 amine
RULE 4 primary_amine
RULE 4 secondary_amine
RULE 4 tertiary_amine
RULE 2 carboxylic_acid
RULE 6 halide
RULE 0 iodine
RULE 2 ketone
RULE 4 phenol
RULE 1 imine
RULE 1 methyl_ketone
RULE 1 alkylaniline
RULE 4 sulfonamide
RULE 1 sulfonylurea
RULE 0 phosphonamide
RULE 0 alphahalo_ketone
RULE 0 oxaziridine
RULE 1 cyclopropyl
RULE 2 guanidine
RULE 0 sulfonimine
RULE 0 sulfinimine
RULE 1 hydroxamic_acid
RULE 0 phosphoryl
RULE 0 sulfinylthio
RULE 0 disulfide
RULE 0 enol_ether
RULE 0 enamine
RULE 0 organometallic
RULE 0 dithioacetal
RULE 1 oxime
RULE 0 isothiocyanate
RULE 0 isocyanate
RULE 3 lactone
RULE 3 lactam
RULE 1 thioester
RULE 1 carbonate
RULE 0 carbamic_acid
RULE 1 thiocarbamate
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RULE 0 triazine
RULE 1 malonic
#other functional groups
RULE 2 alkyne
RULE 4 aniline
RULE 4 aryl_halide
RULE 2 carbamate
RULE 3 ester
RULE 5 ether
RULE 1 hydrazone
RULE 0 nonacylhydrazone
RULE 1 hydroxylamine
RULE 2 nitrile
RULE 2 sulfide
RULE 2 sulfone
RULE 2 sulfoxide
RULE 1 thiourea
RULE 1 thioamide
RULE 1 thiol
RULE 2 urea
RULE 0 hemiketal
RULE 0 hemiacetal
RULE 0 ketal
RULE 1 acetal
RULE 0 aminal
RULE 0 hemiaminal
#protecting groups
RULE 0 benzyloxycarbonyl_CBZ
RULE 0 t_butoxycarbonyl_tBOC
RULE 0 fluorenylmethoxycarbonyl_Fmoc
RULE 1 dioxolane_5MR
RULE 1 dioxane_6MR
RULE 1 tetrahydropyran_THP
RULE 1 methoxyethoxymethyl_MEM
RULE 2 benzyl_ether
RULE 2 t_butyl_ether
RULE 0 trimethylsilyl_TMS
RULE 0 t_butyldimethylsilyl_TBDMS
RULE 0 triisopropylsilyl_TIPS
RULE 0 t_butyldiphenylsilyl_TBDPS
RULE 1 phthalimides_PHT
RULE 2 arenesulfonyl
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